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Summary 
Although practice guidelines1,2 for the management of AIH exist, they are based on data from many 
years ago and may not be reflective of actual current practice. Therefore, this study investigated 
current practice and outcome in the UK’s first large-scale multicentre audit involving 28 hospitals. 
This has characterised 1267 patients presenting to hospitals of varying size, expertise and facilities 
across several regional areas.   
Major findings were: 
• Patients were older than those from other multicentre studies overseas and some single-centre 
studies, indicating that AIH may affect older people in the UK and should be considered in older 
patients more readily.  
• One-fifth of cases had ≥12-month diagnostic delay, though this study did not demonstrate worse 
overall outcome, one does not know the impact of this delay on longer-term outcome 
highlighting inefficiency in diagnosing this rare condition.  
• There is under-reporting of key histological features, especially in DGH’s. The effect of this on 
diagnosis is emphasised by findings that simplified-criteria, as utilised, failed to diagnose one-
third of patients.  
• Independent baseline predictors of all-cause mortality/transplantation were age, 
cardiac/respiratory co-morbidity, black ethnicity, cirrhosis, decompensation, low platelets and 
peak bilirubin. 
• Independent baseline predictors of liver-related mortality/transplantation were cirrhosis, 
decompensation, low platelets and peak bilirubin. 
• Failure to receive corticosteroids or SSA’s are independently associated with adverse outcome 
underlining the importance of always offering patients treatment in the absence of 
contraindications. 
• Higher dosages of prednisolone have a 2-fold increased risk of all-cause death/transplantation 
urging use of caution when considering dosing regimens. Type of steroid used does not affect 
overall outcome. 
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• Serum ALT at 1 and 3-months was an independent predictor of outcome of LRD/transplantation 
and could be used as a useful prognosticator. 
•  There is variability in service provision between hospitals, with better provision of specialist 
clinician’s and nurses at UH’s, with AIH often managed by a larger number of clinicians than 
necessary. Liver blood test monitoring was inadequate and referral to/discussion with transplant 
teams were not done in all decompensated patients potentially eligible for transplantation. This 
supports the case for AIH to be managed by a smaller number of designated clinicians, 
improving patient monitoring and the rate of transplant referral. 
• Histopathologists with a specialist-interest in liver disease improved reporting of at least some 
histopathological findings of AIH calling for the expansion of Histopathologist numbers, 
improved liaison between centres, sharing clinical experience and encouraging adherence to 
guidelines to improve patient care. 
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Chapter 1: Introduction 
In the 1940’s, the term Chronic active hepatitis was initially ascribed to patients with symptoms 
presumed to be of a persistent viral hepatitis, that did not settle. In those who were asymptomatic 
but whose laboratory features continued, were said to have chronic inactive hepatitis. In these 
times, autoimmunity was not a commonly recognised clinical phenomenon and the lack of 
availability of testing of autoantibodies and liver sampling would hamper recognition of this.  Later, 
there were suspicions that these clinical episodes pertained to a separate clinical entity of chronic 
hepatitis.  
 
In 1950, both Swedish physician Jan Waldenström and American physician Henry Kunkel separately 
described the clinical phenotype of young females with chronic liver disease who had 
hypergammaglobulinaemia. 3,4 They described symptoms of fever, arthralgia and demonstrated 
plasma cell infiltration on liver biopsy in these patients. The patients were often referred to as 
‘Kunkel-Waldenström girls’ by followers of their work. It was later described that “altered liver 
proteins” stimulated the formation of “anti-liver antibodies” which in turn produced liver injury, 
perpetuating more altered protein release thereby causing further hepatic necrosis. 5  
 
Appropriately, the term autoimmune hepatitis (AIH) was eventually adopted after the earliest 
meeting of the International Autoimmune Hepatitis Group in 1992 where the diagnostic criterion 
was codified. We now recognise the collection of characteristics of raised serum transaminases, 
hypergammaglobulinaemia, positive autoantibodies, and representative histological changes on liver 
biopsy with steroid responsiveness to be classical AIH. 
 
AIH is recognised to be a chronic unremitting autoimmune inflammatory parenchymal liver disease 
of undetermined aetiology. However, there is increasing evidence of its association with other 
autoimmune diseases, HLA associations,6,7 evidence of immune over activity and typically responds 
to immunosuppression.1 Left untreated this condition can progress to cirrhosis, liver failure and 
death.  
1.1 Epidemiology 
There are no published data on the incidence and prevalence of AIH in the UK.   
The European annual incidence of AIH is between 0.8-1.9 cases per 100,000 per annum,8-10 and it has 
been suggested that it is increasing perhaps because of the ‘hygienist theory’ (improved hygiene 
leading to reduced infections).11  
15 
 
Prevalence data from Spain, Scandinavia and New Zealand indicate ranges from 10-24/100,000.8,9,12-
14  Interestingly, in one homogenous population of Native Alaskans, the point prevalence was 
reported as 42.9 per 100,000. 15 
 
Females are affected 3-4 times more commonly than men in type 1 AIH but in type 2 AIH this sharply 
increases to a 10:1 ratio. 16 Type 1 and type 2 AIH are denoted by their antibody profile; which is 
discussed in more detail later in this review.   
 
AIH can affect all ages and ethnic groups worldwide. 17-22 Age appears important because older 
patients have a higher all-cause death/transplant,23,24 but in some reports younger age was 
associated with liver-related death/transplant. 25,26 
 
Ethnicity has been associated with variations in disease severity and outcome. African-Americans are 
more likely to be cirrhotic at index presentation (56%-85%) versus 38% in patients from Northern 
Europe. 21,27   One retrospective single-centre UK study found non-Caucasian patients; specifically 
African, Asian and Arabian presented at earlier age (p<0.05), were more likely to have cholestatic 
biochemical features (p=0.014) and were also less treatment responsive (p<0.0005) than white 
(European Caucasoid; EC) patients. 18  This small study had only 12 patients who were non-EC as 
compared to 180 of EC origin and thus the former were a relatively small representation of all their 
AIH patients.  Such diverse presentations and features may signify different genetic predispositions, 
environmental exposure, cultural and socio-economic circumstances. 28   
 
Several viruses (hepatitis A, Hepatitis E, CMV and EBV), use of medications and even herbal 
medicines have been reported to precede cases of AIH. 1 
 
Drug-induced AIH (DIAIH) 
Up to 9% of AIH cases could be drug-induced; with Nitrofurantoin and Minocycline being the most 
frequently associated. 29 A chronic active hepatitis of varying degrees has been shown to be induced 
by Nitrofurantoin but there is no consistent correlation with dose or duration of therapy, which is 
unlike an ‘ordinary’ drug-induced liver injury (DILI).30 Often histological patterns seen with 
Minocycline, Nitrofurantoin, Statins and Khat are indistinguishable from AIH. 31,32 
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A large retrospective study of consecutive AIH patients (n=237) made a comparison with DIAIH 
(n=24) and found they had similarly raised antinuclear antibodies (70% versus 83%) and smooth 
muscle antibodies (45% versus 50%). 29 
 
The complexity of the relationship between drugs and AIH can be seen with Anti-TNF agents 
(Infliximab and Adalimumab). This is demonstrated by the fact they have been successfully used in 
treatment-refractory AIH patients 33 but they have also been implicated in causing both drug-
induced liver injury (DILI) and DIAIH. 34 In practice, it is often difficult to distinguish between DILI and 
DIAIH. Unlike DIAIH, usually, a DILI will usually resolve and not recur. 
 
Reported associations between AIH and many other drugs such as Methydopa 35 and Clometacin 
(Non-steroidal anti-inflammatory) 36 are based on single or small case series may just be 
coincidental.  
1.2 Genetics 
Studies of major histocompatability complex (MHC) genes which are located on the short arm of 
chromosome 6, have given insight into the genetics of AIH because they mediate interactions with 
leucocytes, in particular, those that code for human leucocyte antigen (HLA) are present in higher 
frequency.   The MHC is divided into Class I, II and III with different genes belonging to each. It is 
variations in the MHC region that are important. 
 
In Type 1 AIH susceptibility has been linked to HLA class II genes, which are highly polymorphic, and 
mapped to the HLA-DRB1 region. 37 In particular associated with DRB1∗03, DRB1∗04, and DRB3 
alleles in White-European and North-American patients. HLA-DRB1∗0405 and DRB1∗1301 alleles are 
seen in Latin America, with DRB1∗04 in Japan and DRB1∗03 or DRB1∗13 in Brazil. 38  
 
A genome-wide association study was performed in the Netherlands and it has further corroborated 
that type 1 AIH has strong links to the MHC region, in particular, association to the amino acid lysine 
at position 71 in the HLA DR β chain (which is encoded by HLA-DRB1*0301 and HLA-DRB1*0401) and 
also found a non-HLA gene; SH2B3 to be a risk factor. 39  HLA-DRB1*04:01 or *03:01 positive patients 
are recognised in revised International Autoimmune Hepatitis Group diagnostic scoring (IAIHGS) 
systems and produce higher mean diagnostic scores and may be considered as ‘risk alleles’, 
indicating phenotypic significance. 7,40  
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Few studies have focussed on type 2 AIH because of its low prevalence. HLA-DQB1∗0201 and HLA-
DRB1∗07 alleles have been associated thus far. 6,41 Tumour necrosis factor-alpha (TNF-α) gene 
promoter (-308A allele) has been associated with a higher risk of developing AIH (OR=1.67). 42 
1.3 Pathogenesis 
The pathogenesis of AIH has not been clearly delineated.  It is postulated that genetically vulnerable 
individuals are exposed to an environmental insult which sparks an immune response; aptly named 
the ‘hit-and-run phenomenon’. This possible infectious agent triggers the immune system, 
potentially many years before being clinically or biochemically evident. 43  A T-cell mediated 
response engages against liver antigens causing necroinflammatory activity within the liver, which is 
then chronically destructive.  
 
Immunopathogenesis 
It is thought that autoantigens initiate ‘molecular mimicry’ or auto-reactivity in AIH as they possess 
similar epitopes, which activate CD4+ T cells causing liver cell injury, which in turn cause plasma cells 
to produce more autoantibodies which perpetuates a vicious cycle. Such autoantigens are identified 
as soluble liver antigen (Anti-SLA) in type 1 disease and Microsomal antibody Anti-LKM-1 can be 
detected in the serum of AIH patients with type 2 disease and the latter are directed against 
Cytochrome P450 more specifically CYP2D6. 44,45  
 
Regulatory T cells (Tregs) normally regulate CD4, CD8 and B cells.  If Tregs are reduced in numbers or 
alternatively defective versions are allowed to proliferate, the liver-specific effectors become 
‘unchecked’.  These effector cells attract monocytes, macrophages and natural killer cells causing 
hepatocyte damage by releasing signals such as interleukins.  Hepatocytes themselves become 
antigen presenting cells utilising HLA class II molecules thus directing or ‘sign-posting’, allowing 
amplification propagating liver damage. T helper 17 (Th17) cells form part of the host defence by 
suppressing Treg cells 46, and higher Th17 levels are associated with the degree of inflammation and 
fibrosis in AIH. 47 Activated T helper cells express C-X-C motif chemokine receptor-3 (CXCR3) which in 
turn binds to ligands such as CXCL10. 48 CXCL10 has been postulated as a biomarker of hepatic 
inflammation and fibrosis. A reduction in serum levels have been said to correlate with reduced 
hepatic inflammation and transaminases following treatment of AIH.49  Treatment aims to restore a 
balance between regulatory T cells and effector cells (T and B cells). 
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1.4 Diagnosis 
A combination of clinical, biochemical, immunological and histological features lead to a diagnosis of 
AIH.  Biochemistry usually reveals a pattern of elevated transaminases; Alanine aminotransferase 
(ALT) and Aspartate aminotransaminase (AST) compared to the alkaline phosphatase (ALP).  The 
degree of elevation does not necessarily indicate disease severity as even minor rises can be related 
to significant histological inflammation. 50 
1.4.1 Clinical Presentation: 
AIH is a heterogeneous disease with presentations reflective of this, therefore, ranging from patients 
with asymptomatic abnormal liver tests to those with acute liver failure (ALF) or end-stage liver 
disease.  Around one-quarter of patients will be asymptomatic at presentation. 12,22,51  Jaundice is 
seen in about 30%, but only a small proportion of these will develop ALF. 41,52 
 
Delayed diagnosis can arise because of the non-specific nature of presenting symptoms. These 
include fatigue, anorexia, nausea, itching, amenorrhoea, arthralgia or abdominal pain.  Macular-
papular rash and fever are less common manifestations.  
1.4.2 Immunology 
(i) Immunoglobulin G 
Elevated immunoglobulin G (IgG) in patients with AIH was originally described in 1973 when one 
group tested levels in AIH patients and compared it to those with other causes of liver disease. 53  
They discovered the mean level was almost three times higher than controls. Levels can be elevated 
in both type 1 and type 2 AIH but in 25% of the latter, they can be normal. 54  It is also of note that 
the range considered to be normal varies widely and may explain why some patients appear to have 
normal IgG at presentation but when they are subjected to treatment this level falls. 2 An isolated 
elevation of IgG without cirrhosis with compatibly elevated transaminases would be typical of AIH. 
 
Antibody isotype immunoglobulin G is normally responsible for binding to, and incapacitating 
pathogens, allowing their recognition and eventual destruction via phagocytic immune cells.  
Elevated IgG is one of the most important parameters to look for when diagnosing AIH 40, and will be 
elevated in up to 90% of cases. 55-57 IgG has also been used for monitoring response to 
immunosuppression and determination of remission. 
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(ii) Autoantibodies  
Several autoantibodies are associated, but not exclusive to AIH including anti-nuclear antibody 
(ANA), anti-smooth muscle antibody (SMA) and type-1 liver kidney microsomal antibody (Anti-LKM-
1). They form a key part of the diagnostic scoring system.  The Antibodies against Soluble Liver 
Antigen and Liver pancreas (Anti-SLA-LP) are linked with severe AIH and adverse outcome and is the 
only disease-specific autoantibody. 58,59 Fifteen to twenty-five per cent of patients have no 
detectable autoantibodies at diagnosis. 41,60  
 
No particular ANA pattern is specific to AIH and staining can be similarly seen in chronic viral 
hepatitis and drug-induced hepatitis. 29,61  Around 35% of patients with type 1 AIH are SMA positive 
and between 55-60% have both ANA and SMA positivity. 
 
Anti-LKM-1 and Anti-liver cytosol (anti-LC-1) are associated type 2 AIH which originally was thought 
to be more severe and more prevalent in children. However, a recent study in adults indicates that 
patients with type 1 and type 2 AIH do not appear to behave differently in presentation or follow-up. 
62 Type 2 disease appears to be geographically more common in Southern Europe. 63 
 
Anti-mitochondrial antibodies (AMA) can be positive in patients with AIH, but usually occur at low 
titres and do not necessarily indicate PBC overlap but could represent a clinical variant. Czaja et al 
demonstrated that AMA was detectable in 5% of patients with AIH using Eliza.64 
 
Studies have found neither the titre or reduction in level has been definitively associated with 
clinical or histological activity. 65-67  Although, more recently it has been shown that after treatment 
the presence of SMA >1:80 was significantly associated with the biochemical and histological activity 
(p<0.001). 68  
1.4.3 Histological Findings 
Liver biopsy sampling is useful to confirm diagnosis, stage, inflammation and fibrosis.  There is no 
single pathognomonic feature of AIH on histology.  However there are classical histological features 
in AIH including interface hepatitis (75-87%)12,69 (shown in Figure 1.1); with inflammatory cells 
spreading from the portal tracts permeating into the parenchyma and rosetting (49%)1,69 of peri-
portal hepatocytes, clustering like a ball, in response to lobular injury, representing hepatocyte 
regeneration. There is often mixed inflammatory infiltrate but with a predominance of lymphocytes 
and plasma cells (75-98%). 1,41,69  There are exceptions to this, when AIH presents acutely and can 
have hepatocellular necrosis and cholestasis superimposed on chronic hepatitis. 70 Centrilobular 
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injury with significant hepatocellular necrosis has been observed as a prominent finding in 29% of 
biopsies with AIH and the only feature in 2-3% of cases. 71 
 
Figure 1.1: Interface Hepatitis 
(Image kindly provided by Dr A. McGregor (University Hospitals of Leicester) 
 
 
Another histological finding has been associated with AIH, namely emperipolesis, which describes an 
intact cell penetrating another cell for example a lymphocyte infiltrating a hepatocyte, although the 
significance of this is not certain, it has been included in diagnostic criteria as a corroborating feature 
and occurs in approximately 75-80% of AIH cases. 1,69,72-76 One postulated relevance of its presence is 
the theory that it may induce hepatocyte apoptosis and thus an additional mechanism to 
autoimmune hepatocyte injury. 77,78 
 
Both rosettes and emperipolesis have been shown to be superior to plasma cells and interface 
hepatitis as independent predictors of AIH.69 
 
1.4.4 Diagnostic Scoring Systems 
There have been developments of the diagnostic criteria over time; in 1992 the International 
Autoimmune Hepatitis Group (IAIHG) formulated an initial comprehensive scoring system which was 
revised in 1999 (Table 1.1). This defined probable AIH (pre-treatment score 10-15 or post-treatment 
≥12) or definite AIH (pre-treatment score >15 and post-treatment >17). 40,60  At first glance it can 
seem daunting and complex but is a useful aid where there is clinical uncertainty. This was 
developed primarily for research purposes to compare populations within clinical trials but is 
undoubtedly useful in clinical practice. 
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Table 1.1: International Autoimmune Hepatitis Group Modified Diagnostic Criteria 
(Adapted from Alvarez40) 
Parameter/ Feature  Score Parameter/Feature Score 
Female sex +2 Drug history   
Positive 











Average alcohol intake   
<25g/day (equiv to <3 units in UK) 





Serum globulins or IgG 









Other autoimmune disease(s)  



























Predominantly lymphoplasmacytic infiltrate 
Rosetting of hepatocytes 

















Optional additional parameters 
Seropositivity for other defined antibodies 




Response to therapy   
Remission alone 



















There also exists a ‘simplified criteria’ for diagnosis 72 based on autoantibodies, immunoglobulins, 
liver histology and negative hepatitis virology where ≥6 is probable AIH and ≥7 is definite AIH (Table 
1.2).  Potential problems can be identified with this approach as there is heavy emphasis on titres of 
antibodies which may not be available in all centres and one of the histological criterion to allocate a 
patients biopsy as ‘typical AIH’ is emperipolesis which does not appear to be a validated diagnostic 
feature, both of which are weighted heavily in this scoring system.  The simplified criteria are less 
sensitive than the 1999 criteria and consequently 16% of patients would no longer be diagnosed 
with AIH and might be denied effective treatment. 79 A study from Greece similarly found that the 
1999 criteria was more sensitive in diagnosing AIH 80 There have been other validation studies 
comparing simplified and 1999 criteria; and found both to have high sensitivity and specificity in 
Chinese patients75  and children in the US. 81  
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Table 1.2: Simplified Diagnostic Criteria for the diagnosis of Autoimmune Hepatitis 
(Adapted from Hennes 72) 
Tests  Cut off Points allocated 
ANA or SMA+ ≥1:40 1 









IgG >ULN 1 
>1.1 times ULN 2 
Liver histology (evidence of hepatitis is necessary) Compatible with 
AIH 
1 
Typical AIH 2 
Absence of viral hepatitis Yes 2 
*maximum of 2 points for all antibodies.                                                                          ≥6: probable AIH 
                                                                                                                                           ≥7: definite AIH 
 
Despite the presence of diagnostic criteria, diagnosing AIH requires clinical judgement.  In atypical 
cases not meeting the required diagnostic criteria for AIH in these scoring systems, it may still be 
appropriate to treat and monitor response.  
1.4.5 Overlap syndromes 
Overlap syndromes are also referred to as variant syndromes and are said to be present when a 
patient displays two concurrent or sequential autoimmune liver diseases such as AIH and Primary 
Biliary Cirrhosis (PBC) and are denoted AIH/PBC overlap or in the case of overlap with Primary 
Sclerosing Cholangitis (PSC) as AIH/PSC.  There is also the possibility of small duct PSC when patients 
have a cholestatic blood profile but typical changes of the large bile ducts on Magnetic Resonance 
Cholangiopancreatography (MRCP) or Endoscopic Retrograde Cholangiopancreatography (ERCP) are 
not seen but there are changes present on liver biopsy consistent with degeneration or paucity of 
the bile ducts.  
 
Variant syndromes with biliary features present the clinician with the problem of determining which 
is the predominant disease and be willing to change treatment approach when the disease courses 
changes. 82 In particular up to 50% of children with AIH in one study had biliary features.83 
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1.5 Management of AIH 
Characteristically AIH responds well to steroid therapy and is included in the diagnostic repertoire 
for this reason.  The purpose of treatment is to suppress the autoimmune inflammatory process 
affecting the liver. Consequences of failing to treat AIH can include progression to cirrhosis, liver 
failure and death.   
 
The benefits of Prednisolone and Azathioprine in AIH were first demonstrated by controlled trials 40 
years ago and have been included in management guidelines ever since. 84,85  There are now  3 
recent management guidelines for AIH which have been produced by the European Association for 
the Study of Liver Diseases (EASL), the British Society of Gastroenterology (BSG) and American 
Association for Study of the Liver (AASLD). 1,2,86  These are based on limited ‘high quality’ data.  This 
is because there are only 11 randomised controlled trials in AIH (7 of initial treatment and 4 of 
maintenance therapy), and all but one performed 25-45 years ago. Thus, many questions remain to 
be answered with regard to the application of “standard” therapy of prednisolone with or without 
azathioprine.  As such, no formal standards of care have been proposed or validated against clinical 
outcomes. 
1.5.1 Which patients should be treated? 
Patients with raised ALT and or AST levels that are more than 5 times the upper limit of normal 
(ULN) who have elevated IgG and/or histological evidence of AIH should be treated.  Trials 
performed in the 1970’s and 80’s showed the clear survival benefit in such patients. In the placebo 
arms of these trials; 3-year mortality was 50%, rising to 90% after 10 years. 84,87,88  82% would 
become cirrhotic if they were not treated. 89  Treatment should also be considered in those with 
symptoms, have cirrhosis and in younger patients with the intention of preventing progression to 
cirrhosis. 90-92  Presence of symptoms is not obligatory to guide the decision to treat because 26% of 
asymptomatic patients can progress on to cirrhosis. 50 
 
Clinical judgement should be exercised in older patients where there is only mild interface hepatitis 
(equivalent to an Ishak necroinflammatory score 4-6) and the presence of relative contraindications 
to steroid therapy.  Evidence suggests that in untreated mild disease there is between a 67-90% ten-
year survival. 93-95  In those who have only mild necroinflammation on liver biopsy, normal 
transaminases and serum globulins or IgG, treatment would not be advocated, as spontaneous 
improvement may occur. Such patients should be monitored. 
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1.5.2 Standard Initial Treatment 
Prednisolone and Azathioprine 
By the 1950’s, it was evident that the outlook of untreated AIH was poor, with 5-year survival rates 
of only 30%. Thus the primary aim of the initial controlled trials of immunosuppression therapy 
completed in the early 1970’s 84,85,87,96 was to reduce this high mortality rate. 
 
The earliest trials of induction treatment for AIH from the 1970’s, showed the efficacy of 
prednisolone (15-20mg) over placebo and azathioprine monotherapy. Improvement of 
transaminases and serum globulins were shown along with a 2-4 year survival advantage. 84,87,88  The 
superiority of corticosteroids comes from their ability to act rapidly, inhibiting lymphocyte activation 
and limiting cytokine production, whereas azathioprine takes months to act. This is because 
azathioprine inhibits maturation of lymphocyte precursors at their origin; inside the bone marrow, 
instead of acting on the numerous circulating lymphocytes. 41 
 
Two key studies from the Mayo Clinic investigated treatment regimens; the first compared 
prednisolone monotherapy (starting at 60mg/day and tapering to a maintenance dose of 20mg over 
4 weeks) versus the combination of 30mg prednisolone with azathioprine 50mg/day versus placebo 
and also versus azathioprine monotherapy. Investigators found that steroid containing groups were 
associated with improvement in serum parameters, histology and survival. The combination of 
azathioprine and prednisolone were accompanied by fewer side effects than prednisolone alone. 85 
In their second controlled follow-up study, they added an additional treatment group (with a starting 
dose of 60mg prednisolone) where the dose was tapered and then titrated dependant on the serum 
transaminases, aiming to keep them less than twice the ULN.  The latter strategy was associated 
with fewer side effects with the maintenance dosage being just 10mg/day, but unfortunately 
histological remission was significantly less in this group. 85,97 
 
Of note, some of the above studies found between 4-14% of patients were Hepatitis B surface 
antigen (HBsAg) positive and none of the previous studies tested for Hepatitis C virus (HCV) as the 
discovery of HCV was not until the 1980’s. In a study from the United States; 8 patients from 105 
‘established’ AIH patients tested positive HBV and HCV. 4% had HBV 4% were also found to have 
positive readings on initial testing with a first generation immunoassay for HCV although this was 
not seen on second testing and probably represents false positivity. 98  It is now common practice to 
attain negative viral hepatitis serology before diagnosing AIH apart from in exceptional 
circumstances. 
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Standard initial treatment in the UK is prednisolone 30mg/day with azathioprine 1mg/kg/day. Those 
who develop initial severe steroid side effects can be switched to Budesonide 9mg/day which is 
discussed later in this review. 1 
 
Other regimens are seen in the American 2010 AASLD guidelines which suggest 60mg prednisolone 
initial monotherapy. 86  This regimen is not used in the UK due to the likelihood of significant steroid 
side effects.  Although this strategy can lead to rapid normalisation of transaminases in non-cirrhotic 
patients, there is no evidence of any overall prognostic benefit. 1,86 
 
Steroid side effects include the development of cushingoid features, diabetes,99 psychosis, 
hypertension, reduction in bone density, osteoporosis and cataracts.  Weight-gain from steroids can 
also often be sustained, even after withdrawal. 100 Corticosteroids can have other unintended side 
effects which can occur such as hastening incidence and progression of atheromatous cardiovascular 
events. 101 In unpublished data from Sheffield, presented at EASL in 2016, showed that hepatic 
steatosis can occur; as seen on 126 paired biopsies at diagnosis (25% at baseline) and increased on 
follow-up to 52%.  The grade of steatosis worsened in 37%, but progression in fibrosis was not 
related to steatosis. 102 These side effects can be limited by the addition of azathioprine 
(combination treatment) which has a ‘steroid-sparing’ effect, allowing lower doses of prednisolone. 
Approximately 5% of patients on azathioprine develop early adverse severe reactions with 
arthralgia, fever and skin rash 103.  Around 10-20% gets nausea and anorexia which often resolves 
with persistence of the medication. Other side effects include pancreatitis, rash and cholestatic 
hepatitis.  Myelosuppression is the most worrisome side effect and therefore monitoring of full 
blood count is warranted.  Thiopurine methyltransferase (TPMT) testing can be helpful in identifying 
patients more likely to get myelosuppression as this enzyme is involved in the metabolism of 
azathioprine into inactive products. 104  One in 300 patients are homozygous for the deficiency in 
enzyme activity and thus severe toxicity will commonly occur, this is where alternatives such as 
Mycophenolate (MMF) should be used.  
1.5.3 Alternative induction therapy for AIH 
Budesonide 
Recently, Budesonide 9mg/day in addition to azathioprine 1-2mg/kg/day has been proposed in non-
cirrhotic patients for 6 months.  Investigators convincingly demonstrated that budesonide when 
compared to those on prednisolone (both with azathioprine) showed more rapid normalisation of 
transaminases (60% versus 38.8%; P= 0.001) and lesser side effects (28% versus 53.4%; p<0.001) 105 
Compared to previous trials this was however a surprisingly low biochemical remission rate in the 
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prednisolone group.  This was a large multi-centre randomised controlled trial (208 patients) where 
viral hepatitis was excluded but unfortunately, no post-intervention histology data was examined 
and as yet there are no long-term data for this treatment regime.  
 
The 90% first-pass metabolism of budesonide lends the advantage of low side effects, but in cirrhosis 
this process is reduced because of haemodynamic factors resulting in shunting of portal blood away 
from the liver and also bypassing effective metabolism and thus not recommended in these patients. 
Its use is in those with significant fibrosis is linked to treatment failure and side effects 106 and also 
potentially increases the risk of portal vein thrombosis.107 Current UK guidelines reflect this and 
therefore offer budesonide as an option for non-cirrhotic patients who have severe or predictable 
steroid side effects.1 
 
There is probably insufficient evidence to advocate its use in steroid intolerant or steroid dependant 
patients. In one study of its use in such patients, 25% discontinued Budesonide due to side- 
effects.108 
1.6 Outcomes of Treatment 
Studies have given rise to a widespread perception that the long-term outlook of treated AIH is 
good. Previously, studies from the US suggested the 10-year survival was 90%. 109,110  However, 
recent studies from the UK showed that when patients are followed up for longer (20-years) survival 
rates fall to 50-70%. 23,111  One older UK study suggested a 5-year survival of 60%, although this was 
partly explained by older age at diagnosis of AIH. 112 This is however, not simply due to ageing 
because it has been established that patients with treated AIH have excessive mortality compared to 
the general population, with standardised mortality ratio of 2-4. 23,113  There is an excess of deaths in 
patients presenting under the age of 45 years, and after more than 10 years of follow-up it appears 
entirely due to liver disease, being only modestly reduced by liver transplantation.  
Such a “late” excess of deaths is probably a consequence of ongoing low-grade inflammatory 
damage and slow progression of fibrosis to cirrhosis. Whilst overall severity of fibrosis stabilises or 
improves on follow up biopsy in treated AIH, such improvement is not achieved in about 25% of 
patients. 114  New development of cirrhosis, which is now uncommon in treated chronic viral 
hepatitis, is eventually seen in 30-50% of patients with treated AIH, a striking indictment of the 
limited efficacy of standard treatment.  Even though its significance has previously been questioned, 
cirrhosis development is important as it is an independent risk factor for long-term mortality. 23,115 
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Early studies focused on survival rates. Later, endpoints of treatment focussed on biochemical 
responses taken as ALT<2 times ULN.  However, things are changing yet again because many 
observational studies suggest those that fail to normalise ALT do worse than those that do.  
One study assessed whether ALT, IgG or γ-globulins correlate with the degree of ongoing histological 
activity on follow up liver biopsy. They found that ALT and IgG were related to histological activity 
indices (p<0.0075) and that if ALT and IgG parameters were both raised this was associated with high 
histological inflammatory activity. 116  If both serum IgG and ALT were normal this was predictive of 
either no (or minimal) inflammation (Ishak necroinflammatory score (NIS) 0-3) or only low-level 
inflammation (NIS 4 or 5).  The authors concluded that such low-level inflammation was an 
acceptable endpoint as they did not observe fibrosis progression in this group. However, others 
suggest that even low-level activity is predictive of long-term mortality. 117 Thus the validity of a 
normal serum IgG as an adequate treatment endpoint needs further evaluation.  
 
Patients who are treated to normalisation of their transaminases, bilirubin and ϒ-globulin levels are 
far more likely to attain histological resolution, but it does not necessarily guarantee it. 118  A recent 
study by Hartl et al demonstrated complete biochemical remission was a surrogate of low 
histological disease activity and was the only independent predictor for histological fibrosis 
regression (relative risk 3.66; 95% CI 1.54–10.2; p = 0.001). They also showed that serial 
measurements of transient elastography were reliable for monitoring disease course. 119  
 
The UK, American and European guidelines agree that normalisation should be the aim of treatment 
because withdrawing treatment before this is associated with relapse and poor outcome. 1,2,86  
 
There are some useful phrases that describe the response to treatment (Table 1.3).  The definitions 
are important as they provide aims, guide management and allow comparison in the literature. One 
always hopes to achieve a ‘complete response’ when treating AIH which equates to marked 
improvements in symptoms, normalisation of serum transaminases and γ-globulins within one year 
and sustained for 6 months.  There is initial non-response in 5-20% of patients. 1,86,120   
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Table 1.3: Definitions of Response 
Response Definition  
‘Biochemical Remission’ Serum Transaminases (ALT and AST) and γ-globulins normalise. 
‘Clinical Remission’ Symptom dissolution.  
‘Histological Remission’ Liver biopsy shows only minimal hepatitis or is normal. 
‘Complete Response’* Either or both: 
Marked improvement in symptoms with ≥50% of all liver tests within month 1 
and transaminases continue to fall below twice ULN within 6 months during any 
reductions toward maintenance therapy. 
OR 
Minimal activity on liver biopsy within 1 yr. 
‘Treatment Failure’ No clinical or biochemical response within 6 months of starting treatment. 
*Definition of complete response taken and adapted from 40. Other definitions are from 121,122. 
1.7 Relapse of AIH 
Relapse has been defined as serum ALT >3 times the ULN and occurs in 50-90% of patients within 12 
months of ceasing treatment. 115,123,124 Relapses are important as they cause ill health, can 
precipitate liver failure, even death, and require reinstitution of corticosteroid therapy with its 
associated side effects.  It is perhaps unsurprising then that multiple relapses constitute an 
independent risk factor for development of cirrhosis and long-term mortality.23,125,126   
A retrospective review of 117 patients in the Netherlands found relapse is almost universal on 
treatment withdrawal. 127 This group defined relapse as ALT >3 times ULN and loss of remission as 
rising ALT requiring reintroduction of drug therapy.  89% either relapsed or had loss of remission 
(47% and 42% respectively). 73% had treatment reinstated within 2 years of drug withdrawal and 
81% within 3 years. 
 
The relapse rate may be reduced by continuing treatment.  As demonstrated in one controlled trial, 
relapse rate was 32% after 1 year following azathioprine withdrawal (but continuing prednisolone 
alone). 128 Relapse rate is reduced to 17% over 5 years if azathioprine is continued in the higher dose 
of 2 mg/kg/day.129  However, there are concerns about increased cancer risk related to long-term 
immunosuppressive treatment in AIH.  A recent report from Sheffield found that the hazard ratio for 
those patients on non-steroidal immunosuppression for less than 4 weeks compared with those 
receiving therapy for more than 10 years compared was 8.7, and was 2.5 when comparing with 
those on therapy for between 4 weeks to 10 years. 130  
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Even normalisation of the biochemical and histological tests does not confer protection against 
relapse; one study showed 60% of patients who relapsed had a prior resolution of inflammation on 
these tests. 118 
 
Preventing relapse using combination maintenance treatment in those with confirmed initial 
histological remission has been shown to be successful; one group found that only 8% relapsed in 
year 1 but increased to 32% when azathioprine was stopped and prednisolone continued. 128 A 
further study compared continuing combination treatment with phasing out prednisolone and 
increasing azathioprine dose from 1mg to 2mg/kg/day in the other group. 129 Reduction in steroid 
side effects was seen in the latter group and relapse did not occur.  In a follow-up study, 83% 
remained in remission for a median of 67 months follow-up. 100 
 
The factors found to be associated with relapse of AIH are longer time to biochemical remission, 
presence of other autoimmune diseases and presence of an initial identifiable disease trigger. 131   
1.8 Other treatments for AIH 
Mycophenolate Mofetil (MMF) 
Mycophenolate (MMF) is a pro-drug of mycophenolic acid and shows potential as an alternative 
agent to azathioprine. Importantly, it has been used comprehensively in the treatment of liver, heart 
and kidney transplant recipients without reported hepatotoxicity. 132-134 
 
Advantages over azathioprine are that it inhibits inosine monophosphate dehydrogenase exerting 
anti-proliferative effects which are more lymphocyte specific. 135  Mycophenolate is generally well 
tolerated with leucopenia and diarrhoea being the main side effects.  Unlike calcineurin inhibitors 
(such as cyclosporine or FK-506), MMF has no neurotoxic or nephrotoxic side effects but is highly 
teratogenic and thus should be used with great caution in women of child-bearing age. 136  MMF is 
also around 10-15 times more expensive than azathioprine. 137 
 
There are a small number of studies that use MMF first-line with an average of 85% achieving 
remission. 138-140 MMF thus far has been shown to be an effective first-line agent but is not currently 
recommended due to its relative expense. Exceptions would include the 0.3% of patients with severe 
TPMT deficiency and those on Allopurinol.  A dose of 2g daily is proposed in the AASLD practice 
guidelines. The CAMARO trial (ClinicalTrials.gov) is currently on-going comparing standard therapy 
(steroid plus azathioprine) versus steroid plus MMF for treatment naïve patients.  
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The vast majority of experience with MMF for AIH is where it has been used in patients who are 
either intolerant or unresponsive to azathioprine. When given for azathioprine intolerance the 
chance of remission is between 43-88% 139,141-146 with the bulk of studies quoting towards the higher 
end of the spectrum percentage remission rates. A UK study showed that MMF plus prednisolone 
induced and maintained biochemical and histological remission in 13 patients who had azathioprine 
intolerance, and they also achieved similar or better rates of fibrosis regression than patients 
receiving azathioprine plus prednisolone. 147 
 
However, when MMF is given in those refractory to standard treatment, the success has been 
variable; studies with only very small numbers of patients quoting between 0-100% remission rates 
139,142,143 but larger case series reporting between 0-64%, 96,141,144,145 with a further small study in 
children quoting a 67% remission rate. 146 One of these recent studies from the Netherlands showed 
that of those in the azathioprine refractory group 27% responded to MMF and only 13% went into 
remission. In contrast, in the AZA intolerant group, 67% went into remission on MMF. 141   
 
In summary, of azathioprine intolerant patients given MMF, many will attain disease remission.  In 
contrast, azathioprine non-response usually predicts MMF non-response.  This probably reflects the 
fact that these patients are likely to have a phenotypically more severe disease and thus a more 
difficult group to treat successfully. MMF does seem to reduce steroid dose and improves 
biochemistry even in these patients. Due to its relative expense, teratogenicity, lack of follow up 
histology, and lack of data on its long-term efficacy and prevention of relapse, MMF cannot be 
recommended as a first-line treatment for AIH.    
1.9 Salvage therapies in non-responsive patients 
When treatment fails, an alternative diagnosis should be considered (such as a variant syndrome or 
in the acute setting; Hepatitis E) and adherence to treatment should be reviewed.  
 
In those not responding to conventional treatment, increased dosages of steroids, and calcineurin 
inhibitors such as cyclosporine A or Tacrolimus can be used successfully 148,149. Rituximab has also 
been used in non-responders to standard therapy150 and in second-line therapy. 151 The B-cell 
depleting properties reduce T cell activation via reducing B-cell help for T cell activation. There are 
other pharmacological agents in development which focus on alteration of gut microbiota, B cell 
modulation and expansion of intrahepatic Tregs by IL-2 or administration, modification, expansion or 
induction of autologous immune cells (adoptive Treg cell transfer). It is not the intention of the 
review to focus on this area in detail. 
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Of course, any patient who does not respond to treatment and progresses to liver failure should be 
referred for liver transplantation and will have a 75% five-year survival with such treatment, with a 
20% recurrence rate. 152 
1.10 Pregnancy 
Pregnancy is normally uneventful in patients with AIH but has been associated with lower live birth 
rate, maternal death, hepatic decompensation and an increased requirement for transplant if the 
patient has cirrhosis. 
 
Autoimmune conditions, including autoimmune liver disease, may improve during pregnancy 
because elevation in oestrogen levels produces anti-inflammatory cytokine effects, protecting the 
foetus preventing immunological rejection. 153  This is the antitheses of what happens in AIH where 
immunological imbalance stimulates cell-mediated autoimmunity. Thus it follows that women are 
more likely to have problems post-partum and may be in part, related to the fall in oestrogen after 
pregnancy. 154 
 
Early data regarding pregnancy in AIH patients come from very small retrospective studies in the late 
1960-1970’s. The earliest included just 8 patients and 4 of these showed deterioration during 
pregnancy; 2 with toxaemia, one with bleeding varices and one with hepatic ascites. 3 mothers died 
within 2.6 years of pregnancy. 155  Another study suggested a high foetal loss rate (33%) and 
prematurity (23%). 156 The latter study did not provide any data on disease flares post-partum but 
did state that 12 of 16 women survived for a mean period of eight years after pregnancy. 
 
More recently, a large single-centre cohort (53 patients and 81 pregnancies) found 33% of patients 
had a relapse of AIH and 78% of these happened post-partum.  11% had serious maternal events, 
defined as death or liver transplant during pregnancy (or within 12 months of delivery) or hepatic 
decompensation during pregnancy (or within 3 months of delivery). 157 
 
Most recently a Danish nationwide AIH cohort (179 births in 103 patients) was studied with 
population controls (1623 births in 1051 age-matched women). They found that fertility in AIH 
patients was unaffected but that they were at increased risk of pre-term birth (OR 3.19 (95% CI 1.53‐
6.64) and smaller babies for gestational age (OR 3.20 (95% CI 0.33‐31.29). There was no evidence of 
an increase in congenital malformations or stillbirths. 158 This data is comparable to a population 
study from Sweden quoting a pre-term odds ratio of 3.21 but did not find smaller children for 
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gestational age.159 Further studies are needed and a population-based data registry may help clarify 
this and also examine the effect of immunosuppression during pregnancy. 
 
Patients are more likely to flare off immunosuppression and can be reassured that azathioprine is 
safe during pregnancy by experience shared so far in patients with AIH, IBD and rheumatoid arthritis. 
157,160,161 Recent data suggest an 11-52% chance of relapse post-partum. 162,163  This wide variation 
reflects the lack of national or international consensus on the risk of relapse post-partum. 
1.11 Predictors of liver transplantation and mortality 
It is known that AIH, especially if untreated, can lead to cirrhosis, liver failure, require liver 
transplantation and cause death. It is imperative to know which features may be associated with 
poor outcome.  
 
The presence of cirrhosis or decompensation has been associated with liver transplantation/death in 
the majority of studies 23,90,111,115,164,165 but not in all. 110,166 
 
The relationship of age to outcome is complex because in some studies younger age has been 
associated with liver death/transplantation 25,26 but in others older age is linked to all-cause 
death/liver transplantation. 23,24,167 
 
Prolonged International Normalised Ratio (INR), failure to respond to initial treatment (or normalise 
transaminases) 26,168 and unimproved day 7 UKELD (end stage liver disease) score (in icteric 
presentations of AIH) have been found to be predictors of poor outcome.169 However one study 
demonstrated that patients who presented with serum AST above 10 times the ULN had a lower risk 
of cirrhosis and had improved long-term outcome.170 Multiple disease relapses, but not single 
relapses, have also previously been identified as a predictor of liver-related mortality. 23,171,172 
1.12 Summary and overall aims of this thesis 
Given that data from studies in Europe and New Zealand have found the incidence of AIH is between 
10 to 24/100,000, this would suggest that between 6-15,000 people in the UK have AIH. Thus, a 
District General Hospital (DGH) in the UK serving a population of a quarter of a million would likely 
have between 24 to 60 patients attending and an estimated 96 to 240 patients for a University 
Hospital serving 1 million patients. These numbers highlight a significant workload for clinicians to 
diagnose, initiate treatment and employ intense monitoring, especially in the early phase of 
treatment of this chronic disease.   
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There are limited data from multi-centre experiences from one country or whole geographical areas 
reporting on AIH. To date the largest collection of AIH cases have come from three multi-centre 
cohorts of 473 Swedish patients which included 10 hospitals 12 and 1313 patients from 31 centres 
collected from the Dutch AIH group;10  focusing on initial presentation, and one further study from 
Denmark including 1721 AIH patients; 14 which presents data on incidence and prognosis but did not 
focus on individual characteristics pertaining to presentation. These cohorts have, however, given 
great insight into the Scandinavian population. This is something we wanted to define further in the 
United Kingdom, but from a wide variety of centres to gain more representative ‘real life’ data. 
Similarly, there are only 11 randomised controlled trials regarding the treatment of AIH and thus 
there are limited data regarding the most efficacious management strategy. Most studies reporting 
the outcome of AIH are from larger specialist units who are more likely to have younger patients and 
patients with more severe disease, because of inherent referral bias, likely because of centre 
expertise and access to liver transplantation.  
 
This literature review highlights several areas that need further study and exploration with regard to 
disease prevalence, optimal management and outcome of patients with varying treatment regimens.   
A significant barrier to answering questions about optimal treatment is that it would be difficult to 
perform large multi-centre randomised controlled trials pertaining to optimal regimens of just 
prednisolone and azathioprine, as funding would be difficult to attain, as we already know these 
medications are effective.  However, one admires the success of multi-centre audits and the insight 
they can offer. For example, the Royal College of Physicians led National Inflammatory Bowel disease 
(IBD) and the National Upper Gastrointestinal bleeding audits have been shown to be beneficial in 
information gathering with regards to current practice and disease outcome and can be used as 
leverage to change guidelines and practice. 173,174   
 
To the author’s knowledge, there are no UK multi-centre audits of AIH, but there has been some 
insight into care for patients with AIH from a 2012 nationwide questionnaire-based survey which 
was designed to give an overview of service provision for liver disease in the UK.175 It found that (of 
106 responding hospitals) DGH’s had fewer Hepatologists than tertiary hospitals (0(0-1) versus 1(0-
10)), and 41/71 (58%) versus 26/35 (74%) respectively had a specialist liver nurse (although this was 
not statistically significant) implying some disparity in staffing. They also found that all hospitals used 
standard therapy as first-line treatment for AIH but when patients were unresponsive or intolerant 
of this, the majority were then referred to a liver unit (74% in DGH’s). Follow-up liver biopsies are 
not frequently performed (in 25% of cases). This indicates some variation in the management of this 
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rare condition. This wide variation in approach to managing AIH was also demonstrated by another 
UK-wide survey of 228 Gastroenterologists and Hepatologists in the same year, with half of the 
respondents indicating that all consultants looked after patients with AIH, Hepatologists were more 
likely to always perform diagnostic liver biopsies than Gastroenterologists (82 vs 58%) and 65% 
continued prednisolone treatment only until transaminases normalised or for up to 6 months, whilst 
others continued for more than 2 years. 176 Given the persistent uncertainty regarding the optimal 
management of AIH, such variation might be expected but whether this affects the outcome is 
unclear. 
 
Although liver disease has been highlighted as a health priority,  resources remain inadequate in 
many hospitals. In 2011, a census of the UK medical workforce164 highlighted few Hepatologists  in 
District General hospitals (DGH’s) compared to University hospitals (UH’s). Of 146 responding 
hospitals; 103 (71%) did not have a Hepatologist and 23 (16%) had no Hepatologist nor 
Gastroenterologist with a specialist interest in Hepatology (GIH). In a 2018 survey of 88 UK Trusts by 
the BSG Clinical Services and Standards committee; 37 of 63 DGH’s (compared to 1 of 27 UH’s) had 
no Hepatologist.177 
 
Networks have been developed for management of patients with Hepatitis C across the UK, with 
similar recent developments in respect to second-line treatments for Primary Biliary Cholangitis. 
These links facilitate provision of specialist advice and when needed, direct care, adherence to 
nationally agreed management guidelines, sharing of scarce facilities, such as transient elastography, 
training for doctors and specialist nurses and finally involvement in research and audit. There are no 
comparable systems for the management of AIH. 
 
At present, there are no formally validated current agreed standards of care that serve as a 
benchmark to compare a Hospital’s performance to, but there are American, European and UK 
practice guidelines1,2,86 which provide some assistance when drawing up standards pertaining to the 
diagnosis, treatment and outcome. 
 
In general, the overall aim of this work to emulate the success of previous audits with our own multi-
centre large-scale audit by deliberately including centres of varying size and facilities. It will firstly 
build a picture of the current numbers of cases of AIH that hospitals are responsible for caring for. 
Secondly it will define current ‘real-life’ practice (diagnosis and treatment) and its relationship with 
the short and longer-term outcome of patients with AIH in the UK. Collecting data on management 
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and outcome from multiple centres allows an analysis of this relationship and should help define and 
validate clinically relevant standards of care for management in AIH. With this work, the aspiration is 
to improve current practice and establish more robust evidence-based guidelines.  Chapter 2 shows 
the audit design. 
1.13 Study Aims 
Methods chapters: 
• Chapter 3 Aim: To produce a user-friendly modified diagnostic tool to validate cases of AIH in a 
step-wise fashion to be used in a multi-centre audit. 
• Chapter 4 Aim: To develop a strategy for retrospectively identifying patients with AIH. 
• Chapter 5 Aim: To produce a robust and secure data collection tool. 
 
Results chapters: 
• Chapter 6 will address the following aims: 
i. To report the number of cases of AIH whom hospitals are managing across Yorkshire (12 
hospitals) and from 16 other hospitals further afield participating in this multicentre audit. 
ii. To report information on diagnosis, presenting features and initial severity of AIH across the 
UK. 
iii. To assess hospitals performance against agreed audit standards below.  
 
Audit Standards pertaining to diagnosis: 
i. 100% of patients will be tested for Hepatitis B (HBV) and Hepatitis C (HCV). 
ii. ≥80% of patients will undergo diagnostic liver biopsy. 
iii. ≥90% of patients will meet the 1999 International Autoimmune Hepatitis Group (IAIHG) 
diagnostic criteria. 
iv. Time from first abnormal LFT’s to diagnosis is <4 months (≥90%). 
• Chapter 7 Aims: 
i. To report the overall outcome (liver deaths, all-cause death and liver transplantation rate). 
ii. To determine any baseline predictors of all-cause death or requirement for liver 
transplantation. 
iii. To determine any baseline predictors of Liver-related death or requirement for liver 
transplantation. 
iv. To determine any relationship between treatment and outcome. 
v. To report initial treatment response and determine any predictors of incomplete response 
to treatment. 
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vi. To report drug toxicity 
vii. To report the proportion of patients maintaining normal ALT, relapse rate and its effect on 
all-cause or liver-related outcome. 
viii. Report disease progression; the development of cirrhosis and determine baseline factors 
associated with its development, new clinical decompensation and Hepatocellular 
carcinoma (HCC). 
 
• Chapter 8 will address the adherence to: 
Audit Standards pertaining to treatment and outcome: 
i. ≥90% of symptomatic patients will receive prednisolone within 4 months of diagnosis. 
ii. ≥90% will continue Prednisolone for at least 12 months. 
iii. ≥80% will have liver blood tests measured 3 monthly. 
iv. ≥90% will attain normal serum ALT within 12 months after the start of treatment. 
v. ≥80% of those with clinical decompensation should be discussed with a transplant centre or 
state a reason why not. 
vi. ≥60% of those re-biopsied (liver biopsy) will attain histological remission.  
vii. ≥75% will not develop de-novo cirrhosis. 
viii. <21% will not clinical decompensation (defined as ascites, encephalopathy or variceal bleed) 
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Chapter 2: Overview of Study Design 
2.1 Audit Background and Conduct 
The original idea to pursue an audit was presented at a meeting held near Sheffield in 2012, 
attended by approximately 45 receptive Gastroenterologists and Hepatologists, mainly from 
Yorkshire and the North of England, to discuss the prospect of gathering information on diagnosis, 
presentation, and outcome of AIH and its associations. There was universal support for this 
endeavour. The venture was also open to centres outside of Yorkshire and interested centres were 
contacted and invited to attend a satellite meeting at the British Society of Gastroenterology (BSG) 
Conference in 2013 in Glasgow.  A protocol was designed in Sheffield (the coordinating centre), then 
reviewed by centre coordinators and revised accordingly. Standards were generated by consulting 
current practice guidelines (BSG and AASLD) and by consensus of consultants at participant centres. 
 
The audit was intended to be conducted both retrospectively (mainly) and prospectively to allow for 
sufficient follow-up time, to provide meaningful results and to allow an overall shorter completion 
time for the project. This meant including both incident and prevalent cases.  Prevalent cases with a 
diagnosis prior to 1/1/2000 were excluded firstly because the criterion for diagnosis was codified 
finally in 1999, and secondly obtaining details about diagnosis and response would be challenging 
prior to this date due to difficulties in viewing medical records from this time period. Lastly, that 
given the earlier diagnosis of these prevalent cases, the fact they had survived may mean these 
cases would be less representative of patients with AIH in terms of outcome. 
 
It was important to try to capture all cases attending each centre otherwise the project would suffer 
from survival bias. The capture strategy is briefly summarised below but the methodology of 
developing this is discussed in detail in Chapter 2. This ensured an approach that did not rely on 
centres own pre-existing lists or databases of patients but allowed an approach that could identify 
patients regardless.  
 
Given the complexities of AIH diagnosis, which is reliant upon clinical, serological and histological 
data, this meant that case validation was needed and a minimally modified version of the 1999 
International AIH group (IAIHG) diagnostic criteria were used.  
 
38 
2.2 Participant centres 
Initially, 29 centres agreed to participate but one later dropped out, leaving 28 centres of varying 
sizes and amenities; there were 14 District General Hospitals and 14 University Hospitals (4 were 
transplant centres): 
 1 Sheffield Teaching Hospitals NHS Trust (coordinating centre), 2Calderdale Royal Hospital, 
3Bradford teaching Hospitals Foundation Trust, 4Addenbrooks, Cambridge, 5University 
Hospitals Leicester, 6Airedale NHS Foundation Trust, 7Chesterfield Royal Hospital, 8Freeman 
Hospital, Newcastle, 9Rotherham Foundation NHS Trust, 10Royal Derby Hospital, 11York 
Teaching Hospital NHS Foundation Trust, 12St James’s University Hospital, Leeds,13Doncaster 
Royal Infirmary, 14Nottingham Digestive Diseases Centre, National Institute for Health 
Research (NIHR) Nottingham Biomedical Research Centre at the Nottingham University 
Hospitals NHS Trust and University of Nottingham,15North Tees University 
Hospital,16Scarborough Hospital,17Darlington Memorial Hospital, 18Manchester Royal 
Infirmary,19Singleton Hospital, Swansea,20Barnsley District General Hospital,21Kettering 
General Hospital, 22Kings College Hospital, London,23University Hospital North Durham, 24Hull 
Royal Infirmary, 25Mid-Yorkshire Hospital 26Royal Gwent Hospital; Newport, 27Stepping Hill 
Hospital, Stockport, 28University Hospitals Coventry and Warwickshire. 
 
Each centre had a ‘local centre coordinator’ (LCC) who enrolled clinical effective audit workers (CE’s) 
to identify patients and enter data. The LCC was also required to register the audit with the Trust 
and liaise with their local information governance team about data transfer. 
2.3 Ethics and Governance 
The project, specifically the strategy used to identify patients and subsequent multi-centre audit of 
practice and outcome has been discussed in full with our local hospital Caldicott Guardian and with 
the research and development department at Sheffield Teaching Hospitals, who determined that 
this was an audit as opposed to research and as such did not require formal ethical approval.  The 
project was registered with our local audit department.   It was also sought to discuss this more 
widely with the Health Research Authority (HRA) who evaluated our protocol and answered our 
questions about reporting the outcomes of our audit. The HRA was happy that this whole project 
was encapsulated within the remit of the audit and it was possible to fully report clinical outcomes. 
The study was approved by the Health Quality Improvement Partnership (HQIP). This study was also 
reviewed and endorsed by the University of Sheffield ethics department (ref 009662).  
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Patients who were alive, were also sent a letter informing them about the audit and that they could 
ask for more information, with a telephone number to ring (of LCC or Specialist Nurse) if they 
required more information or could opt out if they wished (only two patients subsequently did this 
and they were removed from the audit).  
2.4 Funding 
A competitive application was made to Health Quality Improvement Partnership (HQIP) and to the 
British Society of Gastroenterology (BSG) for funding, a total of £50,000 was received. This was 
mainly used to remunerate CE’s time to gather relevant data and to purchase a web-based data 
collection system. 
2.5 Design and Informatics 
Centres were asked to identify and include both incident and prevalent cases by utilising a pre-
validated search technique which included searching electronic clinical records, histology databases 
and hospital coding as well as any pre-existing databases of patients. This is described in more detail 
in Chapter 4.  Patient lists were generated from the search, and cases were then validated using a 3-
stage sequential diagnostic validation form which formed the first part of the web-based data 
collection proforma (see Appendix A).  This part of the proforma used a minimally modified 1999 
IAIHG diagnostic score to make this as uniform and comparable as possible across centres for 
reasons described in detail in Chapter 3. Thus, if the patient scores ≥10 they have at least probable 
AIH. This was only for ease of use of the proforma. (see Appendix A and 1999 IAIHGS in Table 1.1: 
Chapter 1). However, to avoid confusion, scores have then been converted for comparison to other 
studies and discussion in this thesis.  
 
Anonymised details relating to diagnosis, management and outcome of patients with AIH were then 
entered into a password protected web-based electronic proforma. Duplication of patient entry was 
prevented by centres stating whether patients had been managed at other centres or not and cross-
checking between them, where appropriate. No control group was included and thus incidence and 
prevalence data are not calculated. It is also of note that some hospitals only included incident 
patients (Manchester, Cambridge and Mid-Yorkshire).  Information pertaining to individual centre 
infrastructure was competed by centre coordinators and collected on a separate web-based 
proforma. 
 
This information was entered into a custom-built encrypted web-based data collection tool (FORMIC 
solutions), this data was held on an N-3 server and downloaded centrally at Sheffield Teaching 
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Hospitals. There were no identifiable patient details entered; each patient was allocated an audit 
number which only the centre entering the details possessed the key to.  In addition, each centre 
had a unique encrypted username and password to access the system. 
 
Cases were both retrospectively and prospectively captured as per the inclusion criteria. All data 
were collected between 1/1/14 to 30/11/15. 
2.6 Inclusion criteria 
1. Meet minimally modified 1999 IAIHG score criteria or have a clinical diagnosis of AIH and are 
receiving treatment with immunosuppressive therapy. 
2. ≥18 years old at inclusion. 
3. An absence of positive HBV/HCV serology but can include those in whom the result was 
undocumented. 
4. Include patients with overlap/variant syndromes (AIH/PBC or AIH/PSC); as the scoring 
system itself has negative adjustments for positive anti-mitochondrial antibody and biopsy 
changes.  
5. Presented between 2000 and 2015, defined as:  
a) Prevalent cases; those presenting from 01/01/2000 to 31/12/2006 and are still being 
followed up, or 
b) Incident cases; those presenting from 01/01/2007 to date whether they were still alive 
or not.  
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Chapter 3: Creating a user-friendly modified diagnostic tool to 
validate cases of AIH. 
3.1 Background: 
Although the 1999 IAIHG diagnostic scoring system is lengthy, complex and involves using 
information from a number of sources to complete in order to denote the likelihood of AIH, it is the 
most inclusive of scoring systems. 
 
For ease of use, researchers developed a simplified scoring system (simplified criteria) which utilises 
fewer parameters. However, this approach loses some of the integrity of the 1999 system; 
considering less parameters and because of its descriptive histological criterion, which includes 
emperipolesis, that is not usually commented upon in liver biopsy reports. It was found in a small 
study from Sheffield, that 83 of 84 (99%) biopsy specimens had emperipolesis present on second 
histological review, when none of the primary reports including this finding.178 The published 
prevalence from other studies is between 32-65%. 72,179-181 The histological parameters (Interface 
hepatitis, lymphoplasmacytic infiltration, rosettes and also emperipolesis) as used in the simplified 
criteria to determine ‘typical’ features of AIH as described and utilised may inadvertently exclude 
around one-sixth of patients it was felt that it was not a feasible tool for use in the audit. 79  
 
Studies from other centres have not always been completely ‘inclusive’ when identifying patients: 
2008 simplified criteria,182 1999 ‘definite’ cases only,111 1999 with ‘early deaths’ excluded171 and one 
solely reliant on clinical codes for selection.14 This poses the problem of case selection bias of more 
‘pure’ AIH and causes difficulty in comparing studies. Others have used full IAIHG 1999 criteria 
(definite and probable).  12,23,26,109,172 By taking a broader approach one can perform sub-group 
analysis to compare like for like. 
 
Thus, a minimally modified version of the IAHG diagnostic scoring system is described here for use 
within our multi-centre audit to identify patients with AIH. 
3.2 Aim 
To produce a user-friendly modified diagnostic tool to validate cases of AIH in a step-wise fashion to 
be used in a multi-centre audit. 
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3.3 Methodology 
A minimally modified 1999 International AIH diagnostic scoring (IAIHGS) system was used. They are 
referred to as Case Validation Proforma part one (Figure 3.1) and part two (Figure 3.2), to be used 
for patient cases identified by Histology, Electronic Letters or Hospital Coding search. The latter 
proforma includes a list of autoimmune diseases for user reference. 
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Figure 3.1:  Modified IAHGS used in the Multi-Centre Audit – Part 1 case validation 
AUTOIMMUNE HEPATITIS CASE VALIDATION 
 Points Awarded 
HBV sAg and HCV (also HAV, HEV or acute CMV/EBV) 
1 is Positive 
Both Negative 
Results not available for either HBV/HCV 






Histology (Biopsy on which diagnosis based if >1)  
Not done 
Done but result inaccessible 
 
Interface Hepatitis 
Mainly lymphocytes and/or plasma cells 
Rosettes 
None of the above 
Bile duct changes 
Granuloma 
More than mild steatosis (fat); pre-treatment only 
Other Changes (other prominent feature 
















Immunology  (please use your own hospital parameters) 
Highest serum IgG (or globulin if no IgG): 
>2x upper limit of normal (ULN) 
1.5-2.0 x ULN 
1.0-1.5 x ULN 
<ULN or not done 
 
Anti-nuclear, anti-smooth muscle or anti-LKM-1 Ab titre 
>1:80 
1:80 
Titre unspecified or 1:40 
Not done, weak +ve or <1:40, negative 
 
Anti-mitochondrial Ab Negative or not done 
















Biochemistry (first available within 1 yr biopsy) – only if 
abnormal enzymes: 
(Alk Phos (divided by ULN)) /(ALT* (divided by ULN)) ratio:   
<1.5 








TOTAL POINTS <4 Exclude 
*use AST if no ALT  
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Figure 3.2:  Modified IAHGS used in the Multi-Centre Audit – Part 2 case validation 
 
CLINICAL RECORDS REVIEW (HOPEFULLY ELECTRONIC)       
 
Score carried forward from previous page =  
 
Alcohol consumption pre-diagnosis 
<22 Units/wk 






Autoimmune diseases (see list below and tick all that apply) 
Past History or Family Hx of autoimmune disease 




Drug History (everyone awarded 1 point regardless)  1 
Treatment 
Failure to normalise serum ALT or AST with treatment 
Not treated 






(serum ALT or AST >2 times ULN) after prior normal value 
 1 










          Adapted from Alvarez et al 1999 J Hepatology 
 
 
Patients/Family Hx Other Autoimmune Diseases 
Primary Biliary Cirrhosis (PBC)  Polymyositis  
Autoimmune Hepatitis (family Hx)  Primary Sclerosing Cholangitis (PSC)  
Antiphospholipid syndrome (APS)  Psoriasis  
Coeliac Disease  Rheumatoid Arthritis (RA)  
Diabetes (type 1)  Sarcoidosis  
Fibrosing alveolitis  Sjogrens  
Glomerulonephritis  Systemic Lupus Erythematosus 
(SLE) 
 
Haemolytic Anaemia  Temporal Arteritis  
Thyroiditis/Hypothyroidism  Thrombocytopenia  
Inflammatory Bowel Disease (IBD)  Uveitis  
Mixed connective tissue disease  Vitiligo  
Mononeuritis multiplex  Other AI disease (specify):  
Multiple sclerosis (MS)   
  
The rationale for modifying the current IAHG diagnostic criteria is that some parameters are not 
commonly used or may be unavailable in some hospitals and thus may not ‘include’ patients who 
may otherwise have been labelled with AIH. This adjustment refers to the removal of ‘other 
antibodies’ and ‘HLA’ testing from initial scoring.  Although this information was collected, if tested 
for, in the subsequent data collection electronic clinical proforma which follows the initial case 
validation (see Appendix A). This would ensure scores were comparable across centres. 
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The order in which the modified AIH diagnostic tool appears has been chosen specifically to 
minimise wasted time entering further data than necessary. Any patients with HBV or HCV were 
excluded to protect the integrity of our audit, thus if a patient had positive serology for either we 
asked that the case is excluded immediately and no further data should be entered. Although it is 
possible to have both HBV or HCV and AIH one would never be clear on whether the clinical picture 
was because of the former or the latter and their management would be different to a patient with 
isolated AIH.  Those with acute IgM positive CMV, EBV or HEV were included, for later consideration, 
given that these viruses have been thought to trigger AIH. 
 
The histology section was enhanced slightly to clarify that those with more than mild steatosis (a 
common finding in liver biopsies), may suggest an alternate aetiology and thus should score -3 which 
is the same as allocated by the ‘other changes’ category which signifies another prominent feature 
suggesting an alternate aetiology.  There was also an option to indicate ‘biopsy not done’ (scores 0) 
so the user does not incorrectly allocate none of the above (score -5) and penalise scores. 
 
If the patient has not reached a score of 4 by the end of part one, then it is not possible to achieve 
the points needed to make a diagnosis of AIH by completing part two and thus needless to carry on. 
In part 2 of case validation required the patients’ clinical records (unlike part 1 where this data can 
be obtained from electronic laboratory and histology systems). The alcohol section was adapted to 
accommodate the alcohol unit system used in the UK, rather than grams, to simplify the process for 
the user.  The drug history section has been changed; awarding every patient 1 point to avoid the 
data handler (who may be non-clinical) from having to decide whether a drug could be causative, 
but drugs history was requested to be documented. Specifically, whether the patient was on 
Nitrofurantoin, minocycline, Infliximab or had a history of Khat ingestion was recorded. The rationale 
for this lies with the fact there remains difficulty in deciding whether a drug is to blame for a 
serological, clinical and histological picture presenting itself, particularly in the shorter term.  Recent 
evidence suggests that up to 9% of AIH is drug-induced. 29 For this reason, it was the intention to be 
inclusive of patients rather than exclusive. 
 
The original 1999 IAIHG diagnostic scoring system (see Table 1.1, Chapter 1) indicates that scores 
between ≥10-15 pre-treatment or ≥12-17 post-treatment is indicative of probable AIH, and scoring 
>15 pre-treatment or >17 post-treatment indicates definite AIH. The overall weighting of responses 
was changed to accommodate alterations made.  Thus, a score ≥10 with our modified version 
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denotes inclusion into our audit as a case of AIH. The maximal points available are 24 compared to 
29 in the original IAIHG scoring. 
3.4 Conclusion 
A minimally modified IAIHG diagnostic scoring system has been developed here to serve as a 
practical, time efficient tool for use within our multi-centre audit to validate cases of AIH. This tool 
was employed to score patients on our prospective AIH database and cases identified by the capture 
strategy described in Chapter 4. This has been successfully transposed into an electronic format to 
be completed as the initial screening of cases, before sequentially moving on to further detailed data 
entry involving demographics, initial severity, serum parameter values and drug treatment. 
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Chapter 4: Methods for developing a strategy to identify patients with 
AIH. 
4.1 Introduction 
Being able to accurately identify as many patients as possible with AIH is essential to the integrity of 
a multi-centre audit evaluating management and outcome to ensure meaningful results. 
Anecdotally; in the meeting with approximately 45 Gastroenterologists from the UK, it was 
established that most hospitals do not have a saved list of monitored patients (or database) with 
AIH. Such a list is not only helpful for monitoring patients but also enables review of practice.  
Additionally, there is potential to compare data with other centres and can possibly be utilised for 
research purposes, with appropriate approval. Generating such a list would certainly not be instant 
because diagnosing AIH relies on evaluating clinical information, compatible blood tests and 
histology, thus requiring information gathering from different sources to reach a diagnosis. 
 
There was a need to develop a robust, accurate strategy for identifying patients who have AIH. The 
proposed strategy would hopefully ‘cast a net’, allowing retrospective identification of patients who 
potentially had AIH. This would then allow case confirmation by application of the modified version 
of the IAIHG diagnostic scoring system for AIH ,40 shown in Chapter 3 (Figure 3.1 and 3.2),  acting as a 
sieve to retain only those who met the criteria for AIH. 
 
At Sheffield Teaching Hospitals; since the year 2000, one of our dedicated specialist Hepatology 
nurses has diligently kept a prospective list of patients with AIH. The main function of which was to 
keep a record of patients who were on treatment and aid monitoring of blood tests. 
 
One wanted to see if it was possible to identify all patients on the database with a proposed search 
strategy and proceeded to first test this strategy within our own centre (Sheffield) and validate it 
against our prospective database.  The resultant cohort of patients from the time frame chosen 
would represent the incident cases of AIH from 1st January 2007 to February 2013. Once validated, 
this capture strategy could then be utilised by all participating centres involved in the audit. 
4.2 Aim 
To develop a strategy for retrospectively identifying patients with AIH. 
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4.3 Methods: 
A retrospective search was performed interrogating three facets; histology database, electronic 
letters and hospital coding (for patients admitted with a diagnosis of AIH). The search period was 1st 
January 2007 to February 2013 as follows: 
 
1. Histology Search 
Sheffield Teaching Hospitals histology database was searched using histological ‘SNOMED’ codes 
used to denote different histological descriptions and indicate diagnoses. After discussion with our 
local Histopathologist, a list of liver biopsies (code T-62000) performed was generated.  The terms 
‘chronic inflammation’ (code M-43000), ‘acute inflammation’ (code M-41000) and ‘acute hepatitis 
NOS’ (code D5-80140) were used. This is because our histology database was not reliably searchable 
for ‘autoimmune hepatitis’ as a diagnostic code, so these more general terms had to be used.  The 
list generated from the database included the hospital number, name and date of biopsy and then 
case validation was performed in three stages: 
(i) Patients who were Hepatitis B (HBV) and Hepatitis C (HCV) positive were excluded 
immediately to prevent unnecessary time spent collecting further information. (Figure 3.1, 
Chapter 3) 
(ii) The list was then reduced by cross-referencing with histological, immunological and 
biochemical data from the hospital results reporting system depicted in the first part of the 
scoring system used to determine if a case meets initial criteria for AIH. If the patient scored 
<4 they were excluded. (Figure 3.1, Chapter 3) 
(iii) If the case scored ≥4 then the second part of the case validation proforma was used with 
reference to the electronic letters system. Of note the maximal number of points that can be 
allocated in this second part of the form is 6; this should be added to the score carried from 
the first part of the form.  Thus, patients with a score of ≥10 meet the criteria for AIH (see 
Figure 3.2, Chapter 3). This process took approximately 5 working days to complete for our 
data sample of 1470 patients initially identified by the search. 
 
2. Electronic letters Search 
In Sheffield there is a departmental ‘S’ drive within our hard drive which can be accessed to view 
typed letters containing up-to-date information about patient’s hepatology clinic appointments. This 
system was started in 2006 and all letters were searched and not restricted by date.  
The search terms ‘autoimmune hepatitis’, ‘auto immune hepatitis’, ‘chronic active hepatitis’ and 
‘AIH’ were usedusing the ‘search-term’ function available on the windows system. The patients’ 
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hospital number, name, approximate date of diagnosis was entered into an Excel spreadsheet. This 
took approximately two working days to complete. These cases were then verified by utilising the 
case validation tool. This process took approximately another 3 working days to complete. 
 
3. Hospital Coding Search 
The coding department was contacted and were requested to search their records for the ICD-10 
codes K45.4 (AIH), K73.2 (chronic active hepatitis) and K73.9 (chronic hepatitis unspecified) 
pertaining to AIH patients. They provided us with a list of hospital episodes between the dates of 
1/1/07 to 28/2/13; these were in-patient admissions or attendance for day case procedures such as 
liver biopsies.  Duplicate patients were removed. This list was then subjected to the case verification 
process as described above. The whole process took approximately 2 working days to complete.   
The same case validation tool was then applied to our own prospective database. 
4.4 Results 
Our Prospective database (our gold standard): 
As of mid-February 2013, this database contained a total of 242 patients.  66 of these patients 
presented after from 2007 onwards. When scored with the case validation tool these cases all 
scored 10 or more, meaning they all met the criteria for AIH as per the modified 1999 AIH score. The 
average score was 14 (range 10-21). The number of patients and scores are shown in Figure 4.1. 
 




























Anticipated capture rates: 
After examining the AIH database, it was evident that 4 patients did not have biopsies performed in 
Sheffield (or did not have biopsies) and 9 patients presented after the search strategy was applied 
and thus have not been found by this search. Hence, 53 patients remain that should be captured by 
a histology search.  One would expect that most patients should be identified by an out-patient 
letter search unless admitted acutely and transferred elsewhere. From the 66, 4 patients presented 
after our search was performed and thus our expectation would be that all the remaining 62 
patients should be identified. It is not possible to say how many should be identified in the coding 
search as not all patients are admitted with this condition.  
 
Histology: 
The histology coding for liver biopsies with chronic inflammation yielded 1470 patients. A separate 
search using ‘acute inflammation’ and ‘acute hepatitis NOS’ search terms only yielded total of 4 
patients; 2 were AIH cases diagnosed prior to 2007 (and also duplicates of those found in the 
‘chronic inflammation’ search), therefore excluded. The remaining 2 cases had an alternate diagnosis 
on review of their liver histology meeting documentation and letters. Thus, no additional AIH 
patients from those identified in the chronic inflammation search were identified. So overall this 
meant 1470 patients were our starting point prior to case validation. 
 
A total of 633 patients were excluded because their viral markers were positive (HCV; 396, HBV; 236, 
1 patient was excluded for EBV positivity, sepsis and an implicated causative drug). 263 patients 
were excluded as their only histological diagnosis was fatty degeneration. 
 
After the initial phase of case validation (found to score 4 points or more), there were 167 patients 
were found to score 4 points or more on the initial phase of case validation using the terms ‘chronic 
inflammation’. 49 cases were excluded by the second phase of scoring and 51 were found to have 
been diagnosed prior to the year 2007 (n=47) or were from out of area (n=4) and therefore excluded 
(See Figure 4.2). 
 
This left 67 patients who had liver biopsies (all in the chronic inflammation group), all scoring 10 or 
more in the case validation, thereby indicating a diagnosis of AIH. There were 12 other patients who 
did attain 10 or more points but had been given another diagnosis following review of their clinical 
case notes, histology and discussion at the liver histology meeting.  In all of these cases, another 
diagnosis was evident and thus were excluded.  
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Of 67 the patients who were diagnosed after 2007; 47 matched our pre-existing database. 20 
patients identified did not match our list of known patients (Table 4.1). Of these, 9 patients were not 
found by any other modality and thus found unique to this facet of the capture strategy (Table 4.2). 
 
Table 4.1: Histology search  
Snomed search No of overall cases 
identified 
No of known Pt’s on AIH 
database identified 
Not on known  AIH 
Database 
Chronic inflammation 67 47 20 
Acute inflammation 0 0 0 
 
Table 4.2: Additional Histology patients identified and number found by other sources 
 Not on known 
AIH Database 
Found in ‘Letters 
Search’ 
Found in ‘Coding 
Search’ 
Uniquely found by 
‘Histology search’ 
Chronic inflammation 20 5 7 
(2 also in letters) 
9 
Acute inflammation 0 0 0 0 
 
Overall, 47 (88.7%) patients were identified from 53 patients with liver histology on the database. 
There were 6 (11.3%) patients recorded in the AIH database that were not found in the histology 
- HBV (serology) = 96 
- HCV (serology) = 168 
- Acute EBV + sepsis = 1 
- 8 Supplementary reports 
- HBV (coded) = 140 
- HCV (coded) = 228 




219 biopsies (167 patients) 
- 347 = Scored less than 4 
- 49 = Scored less than 10 
- 52 = Multiple biopsies 
- 51 = Diagnosis prior to 2007 or out of area 
 
67 Patients with AIH 
First part of validation 
applied 
Second part of validation 
applied 
1470 Liver biopsies 
(‘chronic inflammation’, ‘Acute 
inflammation’ & ‘Acute hepatitis NOS’) 
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search. The reasons why this was not complete capture via the histology search were investigated. 
Direct search of the histology database for the 6 remaining patients not identified by the search 
revealed the reason for their absence in our results was a discrepancy or incomplete coding (Table 
4.3). 
 
Table 4.3: Histological codes given to patients who were missed 




‘Deposition of iron and metaplasia’ 1 
Liver biopsy was incorrectly coded as ‘pancreas biopsy’ 1 
 
Realistically, learning from this process it seems that it would not be practical to include searches for 
cirrhosis, necrosis or deposition of iron and metaplasia as these would presumably lead to a huge 
number of patients being identified who are unlikely to have AIH. The liver biopsy coded as pancreas 
is an error, which cannot be foreseen.  There would perhaps be an argument for including PBC as 
this is sometimes seen concurrently with AIH and is a rare disease thus shouldn’t produce copious 
numbers of cases. 
 
Of the 20 patients not included in the prospective database between 2007 and 2013 (Table 4.4); 11 
were found by another facet of the search strategy (letters or coding). Of the 9 patients were unique 
to the histology search: 2 were Nitrofurantoin-induced and settled without treatment, 4 were 
considered mild (not treated), 2 under the care of Gastroenterologists at the Northern General 
Hospital (NGH); thus, not monitored on a hepatology database, and 1 was initially treated and has 
not relapsed but not labelled with a diagnosis of AIH. 
 
Table 4.4: Patients identified by histology search but not in database (n=20) 
Details of those not on database No of patients 
Not treated 8 
Treated*  8 
Nitrofurantoin-induced (not treated) 3 
Defaulted 1 
*3 of these patients were under the general gastroenterologists at NGH. 
 
A further breakdown of those who underwent treatment, who were not in the database, is shown in 
Table 4.5. There are two hospitals in Sheffield (Royal Hallamshire Hospital (RHH) and NGH) that 
receive liver patients, 3 patients came under the latter hospital and therefore not on the AIH 
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database used in conjunction with the liver unit at the RHH. The AIH database was originally created 
to monitor those on treatment and therefore it is unsurprising that the 4 people not on maintenance 
treatment (patients 1-4) are not included on the database.  One other patient not on the database 
(patient 5) had defaulted at the time the database was viewed. 
 
Table 4.5: Treatment and current status of the 8 patients who met AIH criteria and were treated who were 




Initial treatment received Current treatment Status 
Patient 1 11 Yes  not on treatment discharged 
Patient 2 12 Yes, but diagnosis uncertain weaning off steroids current 
Patient 3 12 Yes, then defaulted not on treatment defaulted 
Patient 4 10 Yes, (Khat-induced) unknown defaulted 
Patient 5 13 Yes on maintenance treatment defaulted 
Patient 6 16 Yes, under NGH care on maintenance treatment current 
Patient 7 11 Yes, under NGH care on maintenance treatment current 
Patient 8 14 Yes, under NGH care on maintenance treatment current 
 
Electronic letters 
277 patient letters were identified using the search terms mentioned in the methods. 189 were 
excluded because 70 were diagnosed prior to 2000, 95 presented from 2000-2007 and 24 patient 
cases originated from other sites seeking opinion. This left 88 possible AIH patients presenting from 
2007-2013 which were then subjected to the case validation. 11 patients were subsequently 
excluded by scoring and 3 excluded because they developed AIH after transplantation. 74 patients 
met the criteria for AIH; 62 of these matched our prospective list of patients and thus 12 were 
potential extra patients (Table 4.6).  Therefore, all patients in the prospective database were 
detected by the electronic letters search when it was performed. 
 
Table 4.6: Electronic letters: Patients subjected to case validation and outcome  
No of known 
Patients in 
the Database 










Letters search in 
the database 
Not in known 
Database (Extra 
patients) 
62 88 11 3 62 12 
 
Out of 12 potentially new patients; 5 were also found by other sources (histology, coding and 1 by 
both) leaving a total of 7 unique patients found by this method alone (Table 4.7).  Of these 7 
patients; 1 was acutely transplanted, 5 did not receive treatment for AIH and 1 patient who was 
treated but there was diagnostic uncertainty. 
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Table 4.7: Electronic letters: Additional patients found and other search modality performance 
Not in AIH 
Database 
Also found in 
Histology Search 
Also found in 
Coding Search 
Uniquely found in 
letters search 
12 4 2 
(1 found in histology also) 
7* 
*3 patients did not have biopsies performed or were not performed in Sheffield. 
 
Hospital Coding Search 
The number of hospital episodes generated by the coding department was 194, from 106 different 
patients, presenting to Sheffield teaching hospitals with a coded diagnosis compatible with AIH 
between January 1st 2007 and February 2013. 
 
After reviewing patients’ records, 21 patients were excluded as they were coded incorrectly and had 
obvious alternative diagnoses. This left 85 patients who had a hospital episode during the search 
period. 48 patients were diagnosed prior to 2007 or lived out of area, and a further 6 did not meet 
diagnostic scoring via case validation and thus excluded.  This left 31 patients meeting the criteria for 
AIH identified by this method. 27 (40.9% matched the database of AIH patients and 4 patients did 
not.  However, all 4 were also found in the electronic letters search and 2 of these were also found in 
the histology search. Therefore, there were no new AIH patients identified by this method alone.   
A summary of overall case capture for each search modality is shown in Figure 4.3 and then Figure 
4.4 compares these findings to the database already kept. 
 













‘S’ Drive  
(using AIH search terms) 
Histology database 
SNOMED code search 
(M-43000 and M-41000) 
Hospital Coding 
ICD-10 code search 











Figure 4.4: Actual case capture of search modalities compared with prospective AIH database 
































88.7% of expected patients on 
database identified by Histology 
100% of expected patients on 
database identified by Letters 
40.9% of possible patients on 
database identified by Coding 
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4.5 Discussion 
Overall, the entire multi-stage capture process took 12 full working days to complete but 
successfully identified all patients on the prospective monitoring database. 
 
Our search for patients using the histology search was hampered by the generalised diagnostic 
codes used and thus prolonged the time taken to identify patients.  Searching the histology database 
would have been far simpler had there been coding employed specifically for AIH.  However, any 
histological diagnosis needs to be matched with relevant clinical information to reach an overall 
diagnosis in AIH.  Perhaps a solution would be to code liver histology following a multidisciplinary 
meeting, rather than prior. 
 
The electronic letters system at Sheffield Teaching Hospitals was not introduced until 2006 and 
therefore this aspect would not useful for identifying patients who presented before this and who 
are no longer under follow up. No patients were identified using the search term ‘chronic active 
hepatitis’; this may well reflect that terminology can be very individual to a particular Hepatologist 
or Gastroenterologist, and may now be considered out-dated.  Searching electronic letters was the 
most productive and accurate modality for finding all known patients with AIH and also useful for 
identifying extra patients. However, one of the potential limitations of our search of electronic 
letters was not performing a search of the ‘Gastroenterology drive’ as they have separate drives to 
the Hepatologist’s. These patients were, however, identified by the histology search and thus 
captured by the other facets of the strategy. 
 
The coding modality for identifying patients seems only to be corroborative of patients already 
labelled with a diagnosis, rather than being additive to our prospective database.  This is inevitable, 
as those being admitted for investigation, such as liver biopsy, may not yet have a diagnosis and thus 
would lack a diagnostic code. 
4.6 Conclusions 
This multi-stage capture process is lengthy but proved to be a productive, robust all-inclusive 
capture strategy for Sheffield patients. If utilised, where possible, by other centres then there could 
be the capture of large numbers of AIH patients whose cases can be studied and outcomes could be 
meaningfully compared.  It is acknowledged that some hospitals may be limited by how 
electronically advanced each of the respective systems is for searching for patients.  
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Chapter 5: Creating a clinical proforma and a central data collection 
tool. 
5.1 Introduction 
It has been shown that in some instances a central system for data entry has been successfully 
utilised.  Examples of this are the direct electronic data entry for the Inflammatory Bowel Disease 
Audit (IBD) and registry, 183 and electronic questionnaire scanning for the National Confidential 
Enquiry into Patient Outcome and Death (NCEPOD) audits. 184 It was decided to see if it would be 
possible for our project to use a web-based data collection tool.  Alternative options included using 
Microsoft Excel spreadsheet or Microsoft Access database for data entry but this requires 
knowledge to use this software. 
 
It was decided that it would be prudent to avoid duplication of tasks by potentially using an 
electronic data collection tool whereby data-collection and entry could occur together. The majority 
of information needed to complete a clinical audit proforma could also be completed utilising 
electronic sources in hospitals that hold blood results and liver biopsy reports and electronic letters, 
accessible via a computer. 
 
There are many benefits of collecting data from multiple centres via an electronic method thereby 
allowing secure, password protected entry and would ideally use the secure and reliable NHS-N3 
(National Broadband) server to host the system. Data entered would have any patient identifiers 
stripped before entry and only the centre inputting data would have the key for the attributed 
unique audit ID.  This avoids the need for copious paper records containing clinical information and 
also their transportation either physically or by other less safe electronic transfer such as email after 
entry into a spreadsheet to a coordinating centre.  The process of exploring the options available to 
us is described. 
5.2 Aim 
To produce a robust and secure data collection tool. 
5.3 Methods 
A clinical proforma was produced initially in a draft format which was built from the aims of the 
multi-centre audit described in the study design (Chapter 1). Since UK AIH cohorts have come from a 
few large centres, one was keen to establish the age, gender and ethnic demographic parameters of 
AIH across a broader and more representative section of the population. Therefore, the proforma 
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incorporates questions about the diagnosis and demographics. The main outcome measurement of 
the audit is death (all-cause and liver-related) and liver transplantation, and one wanted to explore 
the associations between these outcomes and (a) drug treatment (drug type, delay in starting and 
duration) and (b) type of centre. In order to achieve this, it was necessary to also collect information 
on (a) presenting features, (b) severity of liver disease and (c) co-morbidity. 
 
Potential surrogate markers of outcome including (a) liver blood test (bilirubin, albumin and ALT) 
response to treatment and (b) development of cirrhosis were also of interest. 
 
The proforma asks for details of drug treatment and provision of blood results on starting treatment, 
monitoring and relapses. Finally, one also had questions pertaining to follow-up liver biopsy, 
pregnancy, complications, admissions, other liver diseases, outcome and transplantation. 
 
The paper clinical proforma is shown in Appendix B. This then went through a peer review process 
receiving input from other centres involved in the audit and where it was felt appropriate, changes 
were incorporated. 
 
To develop a strategy for collecting data from 28 centres onto a single platform, different options 
were considered.  Firstly, a meeting with the local audit team provided some advice and they 
recommended that a Microsoft Access database would be the most powerful tool, especially for 
analysis. However, this requires in-depth knowledge to design such a database and our local audit 
office did not have the manpower to achieve this for us. One was also not confident that every 
hospital would have Microsoft Access software available for use.  In addition, separate databases 
would have to be created for each centre to use and then merge to analyse all the data; this seemed 
a large task and may introduce error.  The audit team considered that a Microsoft Excel spreadsheet 
may or may not be powerful enough to deal with the amount of data being collected. After 
consideration, and a trial with designing a preliminary spreadsheet in Excel for this purpose it was 
found that it looked extremely cumbersome, and if the person entering data were to just make one 
error in one row, for one patient ID, the entire spreadsheet could fail.  
My supervisor Professor Gleeson and I also liaised with the Royal College of Physicians and British 
Society of Gastroenterology audit teams to seek advice on audit tools they used to complete 
national projects. They provided us with names of companies that may be able to help and we 
liaised with them; communicating via email, telephone and in person and in addition with several 
colleagues in other centres about their experiences with different systems. 
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This audit was financially constrained and one needed to find an affordable option that could be 
tailored to our specific project. Several options were explored; including a system provided by ‘Web-
Logik’ – but the cost of such a system was prohibitive:  £11,050 minus VAT plus additional ‘hosting’ 
fees (£16,830 plus VAT) and a company called ‘Net-Solving’ (£9000 plus VAT and £2,400 for hosting 
and £100 for certificates) but they could not offer us secure hosting on the NHS-N3 network which 
would potentially make our data less safe. 
 
Finally, one contacted a company called ‘FORMIC’ which I had heard of whilst working for the 
University Hospitals Leicester NHS trust and we were quoted an overall cost of £12,000 (including 
VAT) plus £2000/year maintenance costs.  References were retrieved from others who used the 
system and considered their experiences to be positive.  The main advantages were that they 
allowed secure hosting on N3-NHS server and had a proven track record of working with hospitals.  
The system also offered an option of filling other facets out on paper and scanning them in which 
could be considered for any patient questionnaires at a later date or on future projects. All data 
entered into this system could then finally be converted into an Excel spreadsheet output file. 
 
A meeting with a FORMIC representative was arranged and one outlined exactly what needed to be 
achieved. It was then necessary to liaise with our local IT department also via email, telephone calls 
and meetings in person to assess the feasibility to install. They advised us to fill out a ‘non-standard 
request’ and advised us it would be possible to install. 
 
However, there were some glitches with the process of instalment and persistence was needed 
whilst being cognisant of the fact that the hospitals IT department had other priorities to attend to. 
Several meetings took place with IT representatives and clinical informatics to resolve installing the 
system.  After several months, the head of IT was contacted who finally facilitated the work for us.  
The system was installed and one day of training learning on how to design, process forms and 
export data was undertaken. The clinical proforma was then transposed over to the FORMIC fusion 
system and drop-down boxes were programmed containing lists or choices, so that data was 
uniform and could be analysed without difficulty. The proforma as it appears for those entering data 
is seen in Appendix A. Its usability and functionality were tested by entering Sheffield’s anonymous 
data, which allowed small improvements to be made. Data entry for the audit was then ‘open’ to 
other centres, once each hospital obtained permission from their respective Caldicott Guardian. 
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5.4 Conclusion 
It is shown here the value of researching others experience of multi-centre data collection. This 
process, as described here demonstrates that it is possible to individually design an electronic web-
based data collection system, with limited funds, without the need to pay an external company to 
complete. Although this took more time than expected, this process produced an efficient, robust 
and secure portal for data entry. 
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Chapter 6: Diagnosis, presenting features and initial severity of 
Autoimmune Hepatitis: A Multi-Centre Audit of AIH 
6.1 Aims:  
i. To report the number of cases of AIH whom hospitals are managing across Yorkshire (12 
hospitals) and from 16 other hospitals further afield participating in this audit. 
ii. To report information on diagnosis, presenting features and initial severity of AIH across the 
UK. 
iii. To assess hospitals performance against agreed audit standards outlined below. 
6.2 Audit Standards pertaining to diagnosis: 
i. 100% of patients will be tested for Hepatitis B (HBV) and Hepatitis C (HCV). 
ii. ≥80% of patients will undergo diagnostic liver biopsy. 
iii. ≥90% of patients will meet the 1999 International Autoimmune Hepatitis Group (IAIHG) 
diagnostic criteria.40 
iv. Time from first abnormal LFT’s to diagnosis is <4 months (≥90%). 
6.3 Statistics 
Software used to analyse data included Excel, SPSS and GraphPad. A t-test analysis was used for 
comparison of groups and when comparing categorical data then chi-square testing was utilised.  A 
p-value of 0.05 was considered statistically significant. 
6.4 Results 
6.4.1 Overall cohort 
1267 patients were included; 80% were female with 103 (8%) not meeting the scoring criteria (score 
<10) but did receive immunosuppressive therapy for AIH. These patients were from 28 participating 
centres (Figure 6.1). There were 1008 (80%) incident and 259 (20%) prevalent cases. Clinical and 
demographic data are presented in Table 6.1. 
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Table 6.1: Demographics 
Characteristic  
Age (Years): median(range) 55 (8-86) 
Female Gender N (%) 1010 (80) 














IAIHG Score: median(range) 17 (2-25) 
Definite AIH: N (%) 
Probable AIH: N (%)  
























BMI in kg/m2: median(range)¥ 27.5 (16-51) 
¥Available in 389 patients 
 
Age distribution is shown in Figure 6.2 and was similar in women (n=1010) and men (n=257); shown 
in Figure 6.3, but between Caucasian (n=1079) and non-Caucasian (n=101) patients there was a small 
peak between 41-80yrs in Caucasian patients and only a small peak between ages 21-40yrs old in 
non-Caucasian patients (shown in Figure 6.4). 
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Median weight at presentation was 72kg (n= 791) with a mean BMI of 28 and median 27.5 kg/m2 
(n=389 with a documented observation).  
 
Figure 6.2: Age Distribution at Diagnosis  
 
 


























































Figure 6.4: Age Distribution and Ethnicity 
 
6.4.2 Clinical features 
Presenting symptoms are shown in Figure 6.5. Although 42% of patients reported jaundice or 
pruritus at presentation, the proportion actually jaundiced (bilirubin >50µmol/L) according to first 
abnormal liver blood tests was 31% (376 of 1196 values recorded) but more so on ‘peak’ bloods 
which was 38% (488 of 1218 values). Nearly one-quarter was asymptomatic. 
Time from first abnormal liver blood tests to diagnosis (defined as date of start of treatment or date 
of diagnostic liver biopsy) was 3 (0-166) months. Time exceeded 4 months in 46% (583 of 1260 
informative patients) and 12 months in 19% (243/1260). The time to diagnosis was shorter in 
patients who presented with jaundice or pruritus than those who did not: 1(0-106) vs 5(0-166) 
months; (p=<0.0001).   
 
There were 546 (44%) patients who had a personal or family history of autoimmune disease, with 
the commonest being thyroiditis/hypothyroidism (15%) and PBC (9%); based on positive AMA (see 
Table 6.2 for a full list of autoimmune conditions at presentation, in order of frequency).  Just over 
1% had a family history of AIH. Major co-morbid conditions patients had prior to presentation were 
recorded (see Table 6.3). 
 
Twenty-three patients (6 with cirrhosis), had taken nitrofurantoin before presentation.  Median AIH 






























subtracted the score then was 12(7-18); and 13 patients still had at least “probable” AIH’.  Nine male 
patients of African or Asian origin, had used Khat (AIH score was 15(8-20) and 10(3-15)) when 
adjusted for drug history, with four still meeting criteria for probable AIH.  One patient was taking 
minocycline and no patient had taken infliximab or interferon therapy either prior to diagnosis. 
 




























Table 6.2:  Personal or family history of Autoimmune conditions  
Autoimmune Condition Personal or Family History  
N (%) of patients 
Thyroiditis/hypothyroidism 191 (15) 
Primary Biliary Cholangitis 115 (9.1) 
Inflammatory Bowel Disease  58 (4.6) 
Rheumatoid Arthritis 55 (4.3) 
Systemic Lupus Erythematosus 43 (3.4) 
Coeliac Disease 39 (3.1) 
Diabetes (Type 1) 30 (2.4) 
Psoriasis 30 (2.4) 
Sjogrens 26 (2.1) 
Mixed Connective Tissue Disease 13 (1.0) 
Primary Sclerosing Cholangitis  11 (0.9) 
Vitiligo 11 (0.9) 
Multiple Sclerosis (MS) 7 (0.6) 
Antiphospholipid Syndrome 6 (0.5) 
Haemolytic Anaemia 6 (0.5) 
Thrombocytopenia (AI) 6 (0.5) 
Fibrosing Alveolitis 3 (0.2) 
Mononeuritis Multiplex 2 (0.2) 
Temporal Arteritis 2 (0.2) 
Uveitis 2 (0.2) 
Glomerulonephritis 1 (0.1) 
Polymyositis 1 (0.1) 
Sarcoidosis 0 (0) 
Family history of AIH 16 (1.3) 
Personal/family history of Autoimmune disease 546 (44) 
N=1267 
 
Table 6.3: Co-morbidity Patients had prior to Diagnosis 
Condition All Patients No (%) 
Cancer 68 (5.4) 
Cerebrovascular disease 32 (2.5) 
Chronic Lung disease 46 (3.6) 
Diabetes 128 (10.1) 
Ischaemic Heart Disease 91 (7.2) 
Non-ischaemic heart disease 34 (2.7) 
N=1267 
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6.4.3 Serum Parameters 
Hepatitis B (HBV) and hepatitis C (HCV) viral serology were negative in 1205 (95%) patients and 
undocumented in 56 (4%). The remaining six patients (0.5%) had negative HBV and HCV serology but 
had other hepatitis IgM antibodies (4 CMV, 1 EBV plus CMV, 1 HEV). 
 
Table 6.4 shows laboratory values at presentation.  Serum IgG values were recorded in 877 patients 
(69%).  Serum IgG or globulin was raised in 78%.   
Table 6.5 shows serum autoantibody data; these were not tested for, or not recorded in 11% 
(ASMA), 12% (ANA) and 27% (LKM-1). Where tested, ANA was present in 57%, ASMA in 47% and 
Anti-LKM-1 in 2%; at least one was present in 83%.  AMA was found in 9%, Anti-SLA was positive in 
10 (24%) of 42 patients tested (in 3 centres); including five in whom ANA/ASMA and anti-LKM were 
negative. 
 
Very few other autoantibodies were tested for: Anti-LP: 1/13 (8%), Anti-LC1: 1/14 (7%) and Anti-
ASGPR: 0/7 (0%). Human leukocyte antigens were rarely tested for; HLADR3: 3/7 (43%), and 
HLADR4: 1/7(14%). pANCA testing was more commonly tested for and where performed: 91/169 
(54%) were positive.  Of those with pANCA positive, only 7/91 (8%) had either a prior diagnosis of 
PSC (n=2 (2%)) or developed it during follow-up (n=5 (6%)). 
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Table 6.4: Serum Parameters at presentation 
Parameter Value No of patients with result 
ALT (IU/L), median(range)  
First ALT 
Peak ALT 








AST (IU/L), median(range)  
First AST 
Peak AST 





















Bilirubin (µmol/L), median(range)  
First Bili                                  
Bili at peak ALT/AST 
                         
                    
19 (2-625) 





Albumin (g/L), median(range) at peak 




   
Immunoglobulin G (g/L), Median(range) 
Peak IgG        
                          
Globulin (g/L) at peak Transaminases, 
Median (range)                          
 
23 (5.8-66.5)  
 







AST:ALT ratio  
Median 








MELD >15, number (%) 216 (17%)  1267 
 
Table 6.5: Autoantibody titres  




1:80 ≥1:80 Positive but 
unknown Titre 
ANA  154 (12%) 484 (43%) 109 (10%) 71 (6.4%) 237 (21%) 212 (19%) 
SMA 137 (11%) 593 (52.5%) 75 (6.6%) 45 (4.0%) 188 (16.6%) 229 (20.3%) 
LKM-1 343 (27%) 904 (98%) 3 (0.3%) 0 (0%) 6 (0.6) 11 (1.2%) 
n=1267 
 
6.4.4 Histological findings (Table 6.6) 
Liver biopsy was performed in 1213 (96%) patients, and of which 1163 (92%) had an accessible 
report. Most had interface hepatitis and a predominantly lymphocyte or plasma cell infiltrate; 
however, only 19% had rosettes (range 0-63%, amongst 28 centres) reported. Emperipolesis was 
reported in only 5 patients (0.4%), from three individual centres. Histology score (1999 IAIHG 
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histological criteria) was 3(-5 to 5).  In 12 patients (1%), all treated as AIH, histology score was -5, 
implying very atypical histology, with seven not meeting 1999 criteria. 
Bile duct abnormalities were reported in 147 (13%) patients; compared to patients without such 
abnormalities, these were more likely to have granulomas (6% vs 1.8%), be AMA positive (28% vs 
6%), and not to meet 1999 criteria (22% vs 6%). 
 
Moderate or severe steatosis was present in 27 patients (2%). In these, diabetes was commoner 
than in those without or with only mild steatosis (26% vs 9%; p=0.007) but body weight and BMI 
values were similar, as was the prevalence of interface hepatitis, plasma cells and rosettes.  
 
The presence or absence of cirrhosis on liver biopsy was undocumented in 6%.  Of 1124 informative 
patients, 254 (23%) had cirrhosis. Ishak fibrosis score (recorded in 539 patients) was zero in 62 
(12%).  The prevalence of cirrhosis did not differ between those diagnosed less than or >4 months 
after first abnormal serum liver tests, nor when 12 months was used as a cut-off. Cirrhosis was 
associated with increased age (p=0.049) but the proportion of those with cirrhosis is shown in 
different age ranges in Figure 6.6 and demonstrates that the relationship is not linear. Ishak necro-
inflammatory score (NIS; range 0-18 or denoted as minimal, mild, moderate and severe) was 
recorded in 688 (59%) patients.  
 
Of the 1086 treated patients whose date of biopsy was known, 246 (23%) were already receiving 
treatment when biopsied. These did not differ significantly from those biopsied before treatment in 
regard to histological features.  
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Table 6.6: Histological features on diagnostic liver biopsy  
Histological Feature IAIHG 
Histology Score 
All Patients (N=1163*) 
No of patients (%) 
Interface Hepatitis 3 1023 (88) 
Lymphocyte/plasma cell predominance 1 869 (75) 
Rosettes  1 222 (19) 
Emperipolesis 0 5 (0.4) 
None of Above -5 9 (0.8) 
Bile duct changes -3 147 (13) 
Granuloma -3 28 (2.4) 
More than mild steatosis   -3 27 (2.3) 
Other predominant pathology -3 16 (1.4) 




























*In whom report accessible 
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Figure 6.6: Proportion with cirrhosis by age range 
 
6.4.5 Simplified Diagnostic Criteria  
Of patients who met post-treatment 1999 IAIHGS criteria (N=1164), 758 met the simplified 2008 
diagnostic criteria for AIH72 and 406 (35%) had insufficient points.  Information was missing in 183, 
but in only 67 patients did this preclude ascertainment of meeting the criteria. After excluding these, 
there remained 339 (31%) of 1097 patients who met 1999 criteria but did not meet the simplified 
criteria.  Of these patients, cirrhosis was present in 18%, and 18% had either clinical decompensation 
or a MELD score of >15. 
 
There were only 26 (2%) patients who met simplified criteria but did not meet 1999 criteria; all 
received immunosuppressant therapy. Of these, 17 were AMA positive (resulting in a deduction of 4 
diagnostic points by 1999 criteria), of 14 with accessible biopsies, 11 had bile duct changes. 
6.4.6 Disease Severity 
Overall, 318 patients (25%) had cirrhosis at diagnosis, based either on liver biopsy (23%), Fibroscan®, 
presence of varices, ascites or encephalopathy.  In only 8 patients was cirrhosis based solely on 
Fibroscan.  The factors found to be significantly associated with cirrhosis at presentation on cox 
regression univariate analysis were age, peak ALT, bilirubin at peak transaminases (>150), serum IgG, 
albumin and low platelets (Table 6.7). On multivariate analysis (Table 6.8) bilirubin at peak 



































cirrhosis. In particular those with bilirubin levels of >150g/L had an associated 89% increase in 
cirrhosis at baseline OR 1.89 (CI 1.12-3.23, p=0.018). 
 
Table 6.7: Factors associated with cirrhosis at baseline presentation (univariate analysis) 
Parameter No of values OR 95% CI P value 
Age 1267 1.008 1.00-1.015 0.049 
Gender  1267 0.92 0.83-1.71 0.832 
Ethnicity 1180   0.459 
PBC  1267 1.038 0.63-1.71 0.882 
Symptomatic  1267 0.96 0.703-1.3 0.78 
Peak ALT  1110 1.00 0.99-1.000 0.001 
Peak ALT/AST >350 1141 1.043 0.79-1.38 0.76 
Peak Bilirubin   1218 0.99 0.99-1.001 0.334 
Peak Bilirubin >150 1218 0.72 0.529-0.96 0.029 
IgG >16g/L 877 2.3 1.49-3.56 <0.0001 
Platelets <150U/L* 1205 4.07 3.01-5.49 <0.0001 
Albumin at peak ALT <35g/L 1047 3.05 2.29-4.01 0.003 
*At start of treatment 
 
Table 6.8: Factors associated with cirrhosis at presentation (multivariate analysis)  











Bilirubin >150 1218 1.89 1.12-3.23 0.018 
IgG >16g/L 877 0.55 0.32-0.95 0.030 
Platelets <150U/L* 1205 0.31 0.206-0.47 <0.001 
Albumin at peak ALT <35g/L 1047 0.30 0.21-0.45 <0.001 
 
108 patients (8.5%) had clinical decompensation at presentation; defined as ≥1 of ascites (n=57 
(4.5%)), oedema (n=70 (5.5%)), encephalopathy (n=22 (1.7%)), variceal bleeding (n=9 (0.7%)).  
MELD score at presentation was >15 in 17% (N=216).  In total 272 (21%) patients had either clinical 
decompensation or a MELD >15. Overall; 74 (6%) patients had varices (on imaging or endoscopy) 
and no patient had Hepatocellular Carcinoma (HCC) at presentation. 
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6.5 Sub-group Comparisons 
6.5.1 Completeness of case capture 
Centres were asked after data collection was complete to state whether they had utilised the full 
capture strategy as intended and the responses are shown in Table 6.9. 
 













Barnsley 33 80-90    ✓ ✓ 




 ✓ ✓ ✓  
Chesterfield 37 100 ✓ ✓ ✓ ✓ ✓ 
Coventry 58 100 ✓ ✓ ✓ ✓ ✓ 
Darlington 14 30   ✓  ✓ 
Derby 106 93 ✓ ✓ ✓ ✓ ✓ 
Doncaster 61 
90 incident, <50 
prevalent 
  ✓  ✓ 
Durham 53 Unsure  ✓ ✓  ✓ 
Hull 35 Unsure    ✓ ✓ 
Kettering 15 70  ✓  ✓  
Kings 44 40  ✓   ✓ 
Leicester 51 90  ✓ ✓   
Manchester 24 95 incident only  ✓  ✓  
Mid Yorks 17 >75   ✓ ✓  
Newport  45 30 (45/140 known) ✓ ✓ ✓ ✓ ✓ 
North Tees 29 Majority  ✓  ✓ ✓ 
Nottingham 100 100 ✓ ✓ ✓ ✓ ✓ 
Rotherham 65 >95  ✓ ✓  ✓ 
Sheffield 161 100 ✓ ✓ ✓ ✓ ✓ 
Swansea 11 10  ✓ ✓   
York 16 >90  ✓ ✓ ✓  
 
Two further analyses were performed to assess if results were distorted by incomplete case capture: 
i) Comparing incident patients presenting between 1/1/2007 to 30/12/2010 (n=488) with 
those between 1/1/2011 to 1/11/2015 (n=520). The only parameter which differed was 
lower mean age at diagnosis;52 vs 54yrs; p=0.04. 
ii) Comparing patients (n=356) in four centres (Sheffield, Chesterfield, Nottingham and 
Coventry) where were confident that the capture strategy described in Chapter 4 was used, 
with the remaining centres (n=911).  Again, most parameters did not differ.  However, 
proportion of patients undergoing diagnostic biopsy (98% vs 95%; p=0.01) and prevalence of 
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IFH (93% vs 86%; p=<0.01), lymphocyte/plasma cell predominance (76% vs 74%; p=0.03) and 
rosettes 34% vs 13%; p=<0.01) was higher in the centres with complete case capture.  
 
6.5.2 University Hospitals (UH’s) and District General Hospitals (DGH’s). 
Patients attending UH’s (n=830) were, compared to those attending DGHs (n=437) more likely to 
have interface hepatitis (89% vs 86%; p=0.01), lymphocyte/plasma cell predominant infiltrate (78% 
vs 69%; p=<0.002) and rosettes (23% vs 11%; p=<0.001) recorded. There was also more complete 
testing in UH’s for ASMA, ANA and LKM-1 (92%, 90% and 75% vs 84%, 84% and 69% respectively; 
p<0.05). Mean age at diagnosis was significantly lower in UH’s: 50 vs 56yrs, (p=0.0001).  
6.5.3 Autoantibody status (Table 6.10)  
Patients who had undergone testing for all three autoantibodies were compared; patients who were 
ANA/ASMA positive (n=654), LKM positive alone (n=17) and autoantibody negative (n=228) 
(although some were AMA positive). 
Those who were LKM positive (n=17) compared to ANA/ASMA positive (n=654) or to autoantibody 
negative (n=228) patients, were younger and more likely to have cirrhosis at presentation.  
Compared to ANA/ASMA positive patients, those who were antibody negative were more likely to 
be male and to have decompensation at presentation. There were no other differences. 
Of AMA positive patients (n=119 (9.4%)), 41 (39%) of 106 accessible biopsies had bile duct changes, 
59 (50%) had a pre-existing clinical diagnosis of PBC and 46 (39%) did not meet 1999 AIH criteria.  
 
Table 6.10: Comparison by Autoantibody* 

















No of Patients 654 17 228    
Age <50: ≥50 236:418 13:4 96:132 0.1 <0.001 <0.01 
Gender F:M 522:132 14:3 52:176 <0.01 0.79 <0.01 
IgG elevated: N (%) 538 (82) 14 (82) 152 (67) <0.001 0.99 0.18 
Histology: No biopsied 
    IFH 
    LPC~ predominance 
    Rosettes 

































Cirrhosis: N (%) 166 (25) 8 (47) 52 (30) 0.44 0.04 0.03 
Decompensation¥: N (%) 134 (20) 6 (35) 77 (34) 0.01 0.14 0.89 
NIS >3 versus ≤3 129:2 4:0 51:2 0.34 0.80 0.69 
*Comparisons only include patients where all autoantibodies were tested for. 
~LPC is lymphoplasmacytic predominance 
 
76 
Compared with patients who had at least one AIH autoantibody (ANA/ASMA/LKM-1) but were AMA 
negative (n=816), bile duct changes were commoner in AMA positive patients (39% vs 10%; 
P=<0.0001 and mean ALT was lower (p=0.002); (Table 6.11). Of AMA positive patients, those with 
the additional presence of AIH antibodies did not differ from those without; (Table 6.12). 
 
Table 6.11: Anti-mitochondrial positive (AMA) patients with other autoantibodies present compared 
 AMA positive AMA negative (≥AIH 
Autoantibody +ve)* 
P value 
No of patients 119 816 - 
Bile duct changes: N (%) 41/106 (39) ¥ 73/749 (10) ¥ <0.0001 
Female: N (%) 103 (87) 645 (79) 0.055 
Age <55:≥55 55:64 383:433 0.92 
Asymptomatic: N (%) 29 (24) 180 (22) 0.55 
Mean peak Bilirubin µmol/L  56.4 87.97 0.039 
Jaundiced: peak bili >50µmol/L: N (%) 24 (20) 321 (39) <0.0001 
Mean peak ALT U/L (SD) 471 (478) 733 (653) 0.002 
Cirrhosis at presentation: N (%) 26 (22) 213 (26) 0.32 
Decompensation at presentation: N 
(%) 
15 (13) 168 (21) 0.047 
Pre-treatment score >10: N (%) 58 (49) 771 (94) - 
Median pre-treatment score N (range) 10 (1-18) 16 (2-22) - 
Score excluding AMA 14 (5-22) - - 
* ASMA/ANA/LKM positive, ¥ Denominator is number of accessible liver biopsies 
 
Table 6.12: AMA positive patients without other autoantibodies present compared 
 AMA positive 
(At least one AIH Ab +ve)* 
AMA positive 
(All AIH Ab’s -ve)** 
P value 
No of patients 66 32 - 
Bile duct changes¥: N (%) 24 (45)^ 10 (31) 0.25 
Female: N (%) 58 (88) 28 (88) 1 
Age <55:≥55 30:36 15:17 1 
Asymptomatic: N (%) 20 (30) 6 (26) 0.33 
Mean peak Bilirubin µmol/L (SD) 54.6 (101) 49.2 (74) 0.09 
Jaundiced: peak Bili >50µmol/L: N (%) 11 (16) 7 (22) 0.58 
Mean peak ALT U/L (SD) 398 487 0.32 
Cirrhosis at presentation: N (%) 13 (20) 7 (22) 0.80 
Decompensation at presentation: N (%) 8 (12) 6 (19) 0.38 
Pre-treatment score >10: N (%) 38 (58) 14 (44) - 
Median pre-treatment score N (range) 11 (3-16) 10 (1-14) - 
Score excluding AMA 15 (7-20) 14 (5-18) - 
* ASMA/ANA/LKM positive, **patients only included if all tested for, ¥ found on liver biopsy ^53 patients had biopsy with available report 
 
6.5.4 Caucasian and non-Caucasian patients 
Non-Caucasian patients (n=101), compared to Caucasian patients (1079): (i) had more men (38 vs 
19%; p<0.01), (ii) presented younger (41yrs vs 54yrs; p=0.0001), (iii) were more likely to be 
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symptomatic (89% vs 79%; p=0.006), to be jaundiced (51% vs 33%; p=0.0002; bilirubin 63(3-702) vs 
27(2-789); p=0.009), and to have clinical decompensation or MELD >15 (30% vs 21%; p=0.046).  
6.5.5 Gender and age 
Male patients (n=257) presented younger (52(8-83) vs 56(8-86)) years; p=<0.0001) and were more 
likely to be jaundiced (51% vs 35%: p=<0.01) and to be decompensated (27% vs 20%; p=0.03), than 
females. Twenty-eight percent of males versus 24% of females complained of jaundice at 
presentation but this was not significant (p=0.3). There were no other differences.  
 
Those presenting aged over 55yrs (n=662) were more likely to be female (83% vs 77%; p=0.007), 
asymptomatic (29% vs 14%: p=<0.01) and cirrhotic (28% vs 21%; p=0.005) and were less likely to be 
jaundiced (34% vs 44%; p=0.0006), compared to those presenting younger. 
6.5.6 IAIHG Score 
Sub-analysis of only those meeting IAIHG scoring for AIH, we found that gender, age and ethnic 
distribution was not different from the entire cohort. 
 
However, patients not meeting IAIHG criteria had significantly lower peak serum IgG: 18 vs 23g/L; 
p=0.004 and a significantly higher albumin at peak transaminases 37 vs 36g/L; p=0.03. There were no 
other significant differences between presenting serum parameters. 
6.5.7 Audit standards: 
Each of the four audit standards pertaining to diagnosis has been assessed and results are shown in 
Table 6.13. Centre-specific figures can be seen in Table 6.14. 
 
Testing for viral hepatitis was recorded as having been undertaken in nearly all patients. However, it 
was not recorded as being performed in less than 80% of cases in 4 individual centres, but these 
were hospitals that were looking after few patients.  
 
Only one centre did not meet the pre-defined minimum of 80% of patients having a diagnostic liver 
biopsy but again this centre contributed very few patients. Overall, those who performed fewer liver 
biopsies had fewer patients meeting diagnostic criteria. 
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Most notably there was a significant delay between the first abnormal LFT’s and diagnosis, with no 
individual centre meeting the pre-defined minimum of 90% of patients being diagnosed within 4 
months. 
 
Table 6.13: Audit standards summary table 










minimum No. (%) 
Tested for HBV and HCV 100 1211 (96) 98 (50-100) 22 (79) 
Had diagnostic liver biopsy+ 80 1213 (96) 97 (71-100) 27 (96) 
Met 1999 IAIHG diagnostic 
criteria¥ 
90 1179 (93) 94 (65-100) 22 (79) 
Time from 1st abnormal LFTs 
to diagnosis is <4 months 
90 54 55 (12-82) 0 (0) 
+performed >90 days after the start of treatment in 42 patients, ¥ Pre- or post-treatment score 
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Table 6.14: Comparison of centre specific data for diagnostic standards 















Airedale 15 100% 93% 93% 60% 
Barnsley 33 97% 97% 85% 27% 
Bradford 47 91% 100% 89% 66% 
Calderdale 40 98% 98% 90% 28% 
Cambridge 45 100% 98% 98% 82% 
Chesterfield 37 97% 100% 100% 58% 
Coventry 58 98% 100% 95% 47% 
Darlington 14 71% 50% 50% 38% 
Derby 106 97% 100% 84% 44% 
Doncaster 61 98% 98% 95% 49% 
Durham 53 89% 96% 98% 58% 
Hull 35 94% 97% 97% 49% 
Kettering 15 100% 93% 93% 23% 
Kings 44 95% 100% 100% 68% 
Leeds 77 95% 100% 91% 71% 
Leicester 51 80% 98% 94% 65% 
Manchester 24 100% 79% 88% 43% 
Mid-Yorks 17 94% 100% 94% 41% 
Newcastle 37 92% 73% 65% 54% 
Newport 45 96% 96% 100% 60% 
North Tees 29 100% 97% 90% 28% 
Nottingham 100 100% 87% 95% 62% 
Rotherham 65 100% 100% 97% 55% 
Scarborough 14 100% 79% 100% 71% 
Sheffield 161 97% 99% 98% 58% 
Stockport 17 100% 76% 100% 12% 
Swansea 11 91% 100% 91% 45% 
York 16 81% 100% 100% 75% 
Average 45 95% 93% 92% 51% 
 
6.6 Discussion 
This large multi-centre study affords several insights into the presenting features of AIH in the UK. 
The salient findings are first, that AIH in the UK affects an older population than reported elsewhere. 
Second, there are often delays in diagnosis, incomplete diagnostic work-up and probable under-
reporting of key diagnostic histological features.  Our findings also call into question, the utility in 
clinical practice of the simplified IAIHG Diagnostic Criteria. 
 
80 
One of the study’s strengths is that it characterises patients presenting with AIH to several hospitals 
of varying size, facilities and expertise. This is one of the largest clinical cohorts of patients of AIH 
reported. There are approximately 170 Acute Trusts in the UK and based on epidemiological studies 
elsewhere, an estimated 8-15,000 patient’s with AIH. Therefore, this study may include 8-16% of UK 
patients. 
 
There are some weaknesses. As in other multi-centre studies of AIH, there was probably incomplete 
case capture, resulting from the complex diagnostic criteria and from difficulties in searching data 
systems.  Despite the presence of a multi-faceted case discovery strategy which found all patients 
with AIH on our prospective database, and some that were not (although this had previously been 
considered to be comprehensive), one can be assured that capture was complete in only four 
centres.  Attempts to address this issue were made by performing subgroup comparisons. This study 
found only trivial difference between (a) the four centres with complete capture and the rest and (b) 
patients recruited 2007-10 and 2011-1/11/15.  Thus, this seems to be a homogenous group and 
probably representative of UK patients with AIH. 
 
This cohort is similar in many respects to other multicentre10,12,14,185 and large single-centre22,23,26,51,111  
cohorts. It has a similar gender balance (71-82%). It confirms a prior observation111 that men with 
AIH present younger than females.  Most patients were Caucasian,  reflecting UK ethnic population 
distribution (87%).186 This was similar to the Dutch cohort (89%)10 and underlines the fact that AIH 
affects all major ethnic groups. Non-Caucasian groups had more severe disease, consistent with 
other reports.18,21,28  
 
Like the Dutch group, this study reports very few patients with a family history of AIH (1.3%) 
suggesting that environmental triggers may play a more important role, although a likely viral or 
drug precipitant was identified in only 3%.  Only one patient had documented acute Hepatitis E virus 
(HEV) shortly before presenting with AIH. The numbers tested for HEV were not ascertained. 
However, in a Dutch study of AIH, no patient had HEV viraemia and EBV antibody prevalence was 
not significantly higher than the general population.187 
 
As with the IAIHG score, this study did not differentiate between personal and family history of 
autoimmune disease. Our figure of 44% was similar to the Swedish group (49% had a personal 
history alone).12 The data collected on the prevalence of specific autoimmune diseases were 
comparable to the review presented in the BSG guidelines. 1  
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However, this cohort is older than other multi-centre AIH cohorts from other countries10,12,185 which 
have a median age at presentation of 43-48 years.  It is also older than in some,51,111 though not all 
single centre studies.13,23 Age at presentation was even older in patients presenting to DGHs than to 
University Hospitals.  This may mean that AIH might affect older people in the UK than in other 
countries. Alternatively, because DGH’s are less subject to tertiary referral bias, this might more 
accurately reflect the “true” age distribution of AIH, which might be older than suggested by most 
published studies (usually coming from large centres). 
 
The varied clinical presentations of AIH reported here are similar to those reported elsewhere,12,22,51 
as is the 25% prevalence of cirrhosis,12,26,51 and the 8.5% prevalence of clinical decompensation.12 In 
this study, 17% had a MELD score >15, thus over one fifth had serious liver dysfunction at 
presentation. 
 
Of the four pre-agreed diagnostic standards, two were met; numbers having a diagnostic liver biopsy 
and meeting 1999 IAIHG diagnostic criteria. However, our standard for diagnostic delay was not met, 
with over 40% waiting over 4 months and 19% at least 1 year. Delay was longer in non-jaundiced 
patients. This could imply that the relatively non-specific symptoms of AIH may not alert the 
physician to this diagnosis. The other postulated reasons for delay could lie with a delay in referral, a 
delay between referral and being seen or delay in obtaining or reporting of liver biopsy sampling. 
The impact of such a delay on disease outcome is unknown. These percentages are open to type two 
errors because some centres had very few patient cases, this may culminate in an exaggerated 
pattern. 
 
Another potential concern is the failure to document Hepatitis B and C serology in 4% of patients, 
this may be because it was performed in primary care, with results often held on separate systems.  
There were also undocumented results for serum autoantibodies commonly associated with AIH in 
12-27% of patients. Other autoantibodies associated with AIH (Anti-SLA/LP, -ASGPR, -LC-1) and 
similarly HLA antigens were uncommonly tested for.  Anti-SLA antibody was found in 24% of patients 
tested and in 10 of 12 patients who were negative for other autoantibodies.  In other studies, SLA 
was found in 43-53% of patients who were negative for conventional autoantibodies. 188,189 It is 




Only 2% of tested patients were positive for LKM-1 antibody AIH (Type 2 disease), similar to in the 
Scandinavian report (5%),12 although contrasting with the Italian experience (23%).51  Differences in 
presentation parameters between ANA/SMA positive, LKM-1 positive and autoantibody-negative 
patients were minor.  The 109  AMA positive patients were more likely (41%) to have bile duct 
abnormalities on biopsy, but many did not, and had otherwise typical AIH, as has previously been 
described.190 
 
Another concern relates to histology reporting. Data was collected from clinical reports, without 
central review.  In 6% of cases, it was unclear whether there was fibrosis or cirrhosis on the biopsy. 
The prevalence’s reported here of interface hepatitis and a predominance of lymphocytes/plasma 
cells are similar to those previously reported (75-98%).1,12,191 However, the prevalence of rosettes 
(19%) is much lower than reported from single centres (49%)191 and the wide variation in prevalence 
between the 28 centres (0-63%) suggests widespread under-reporting.  Similarly, the prevalence of 
rosettes in the Dutch multi-centre study was 16%.10 
 
Emperipolesis was very rarely reported (0.4%). In single-centre studies, reported prevalence has 
been 65%-78%.191-193 In a preliminary study in Sheffield,178 emperipolesis was seen in 83 of 84 of 
patients already known to have AIH but took the Histopathologist 6-10 minutes to assess.   Presence 
of rosettes and/or emperipolesis can help distinguish AIH from viral hepatitis and from drug-induced 
liver injury (DILI).193 Presence of rosettes contributes one diagnostic point to the 1999 IAIHG 
diagnostic scoring system.  It is thought that rosettes represent hepatocyte regeneration after 
lobular injury, and in paediatric patients, has been shown to be the most significant predictor of AIH 
in biopsies with chronic hepatitis.179  Although there is a lack of clarity in the original report,72 both 
rosettes and emperipolesis appear necessary for “typical” histology, earning 2 diagnostic points by 
the 2008 simplified system.  It has been previously observed that 37% of patients with AIH by 1999 
criteria would have been excluded by simplified score if emperipolesis was unreported, but only 15% 
would be excluded if reported.178 
 
In calculating the simplified IAIHG  score, it was deemed the presence of interface hepatitis, 
lymphocyte/plasma cell predominance and rosettes without a detracting finding (such as bile duct 
damage or more than mild steatosis) amounted to “typical” AIH histology, thereby gaining 2 
diagnostic points72. Even with this “liberal” interpretation, 31% of patients meeting the 1999 criteria 
and with sufficient diagnostic information (one-fifth with severe disease), failed to meet the 
simplified criteria. The equivalent figure in the Dutch multi-centre study10 was 18%.  If the study had 
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adopted the more stringent definition of typical histology and also required emperipolesis, then only 
six patients had “typical” histology.  The simplified criteria have been shown to be highly specific for 
AIH in single-centre validation studies,79,80 but missed 5-10% of cases as defined by the 1999 criteria. 
Thus, the simplified system may be too strict to be useful in clinical practice and its rigid application 
may result in non-diagnosis of serious and potentially treatable disease.  Indeed, the low prevalence 
of rosettes, and the rarity of emperipolesis (together with the incomplete testing for 
Immunoglobulins and autoantibodies) in this study raise the possibility of under-diagnosis of AIH in 
the UK. 
6.7 Conclusions 
The results of this large multicentre Audit suggest that AIH in the UK may affect an older population 
than in previous multi-centre studies. It highlights delays in diagnosis, incomplete diagnostic work-up 
and probable under-reporting of important histological features, more so in district general 
hospitals. It calls into question the utility of the simplified IAIHG diagnostic criteria in clinical 
practice. One way of achieving more complete, more accurate, and probably earlier diagnosis of AIH 
might be central corroboration of liver histology in a few larger centres and more explicit guidelines 
for Histopathologists. Histopathological meetings with clinicians and Histopathologists discussing 
cases with relevant information could optimise patient management. 
6.8 Future Work 
The ultimate aspiration of this work was to characterise AIH in the UK and the fulfilment of this 
depends on continuing to collect prospective cases but also to extend this audit to all hospitals in the 
UK. With appropriate patient consent, for example, they could then be offered entry into 
appropriate research studies pertaining to the treatment of AIH.  
 
Please note 
Parts of this work have also been presented orally and in abstract form at National (Digestive 
Diseases Federation (DDF); London, England) and International (European Association of Study of 
Liver disease (EASL) in Vienna, Austria) conferences. An edited version of this chapter has been 
published in Liver International, full permissions have been received.  
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Chapter 7: Management of Autoimmune Hepatitis in multiple regions 
in the UK:  Treatment and Outcomes 
7.1 Aims 
To perform a comprehensive study of treatment and outcome of AIH in 28 UK centres, including 
hospitals in Yorkshire, and several hospitals located in Wales, Trent and the North East. Given the 
sizable cohort of patients included from a number of centres of varied size, there is an opportunity 
to see whether the outcome predictors reported by UK single-centres, often tertiary centres, often 
with only 100-250 patients, are a true reflection of patients across the UK with AIH. 
 
It is hypothesised that there will be baseline demographic, clinical features, serum markers, 
treatment factors, disease relapses and type of hospital will be associated with outcome. It is 
speculated that there will be varied treatment strategies between different types of hospital and 
that this will affect outcome. 
 
Therefore specifically, the study describes: 
i. Overall outcome (liver disease related mortality, all-cause death and liver transplantation 
rate). 
ii. Baseline predictors of all-cause death or requirement for liver transplantation. 
iii. Baseline predictors of liver-related death or requirement for transplantation. 
iv. The relationship between treatment and outcome 
v. Initial treatment response and predictors of incomplete response to treatment. 
vi. Drug toxicity. 
vii. The proportion of patients subsequently maintaining a normal ALT, relapse rate and its 
effect on all-cause or liver-related outcome. 
viii. Disease progression; the development of de-novo cirrhosis and determine baseline factors 
associated with its development, new clinical decompensation and Hepatocellular 
Carcinoma (HCC). 





Participant centres were asked to identify and validate retrospective and prospective cases using the 
detailed methodology described in Chapter 3 and 4.  Information pertaining to treatment and 
outcome was entered into a web-based, bespoke data collection system between January 2014 and 
November 2015 (see Chapter 5).  
 
The primary outcome studied was death or liver transplantation. This was further subdivided into all-
cause mortality or transplantation and liver-related mortality or transplantation. 
 
Decompensated liver disease at presentation was defined as ascites, oedema, encephalopathy, 
variceal bleed or Meld>15. Cirrhosis was defined by liver biopsy, presence of varices, ascites, 
encephalopathy or Fibroscan®. Treatment response was defined at normalisation of ALT by 6 
months. Relapse was defined as two times the upper limit of normal transaminases (ALT and/or 
AST), having previously returned to normal. Follow-up time was defined as time from diagnosis to 
last out-patient appointment, liver transplantation or death.  
7.3 Statistics  
SPSS (version 21) and GraphPad software were used to analyse data. Kaplan-Meier survival analysis 
compared sub-groups using the Log-rank test and survival tables were used to calculate overall 
survival. Variables associated with outcome (all-cause death/ transplantation and liver 
death/transplantation) were ascertained by looking at each variable in univariable analysis and those 
with p<0.10 were then assessed using a backward stepwise multivariate Cox regression analysis to 
elucidate which may be independently associated with outcome.  Binary logistic regression was used 
to calculate odd ratio’s. Chi square test was used to calculate differences between proportions and t-
test was used for non-parametric data with means and standard deviations quoted. Medians were 
used to describe continuous data with ranges. P<0.05 was considered statistically significant. 
7.4 Results:   
7.4.1  Overall Outcome 
Of 1267 patients; 1110 (80%) were female, the median (range) age at diagnosis was 55(8-86) years 
and follow-up was 3.8(0-15) years.  At diagnosis, 318 (25%) patients had cirrhosis and 74 (6%) had 
clinical decompensation. There were 272 (21.5%) overall who were decompensated (clinical 
decompensation or MELD >15).  
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Overall 1.2% patients died from liver disease, 2.3% underwent liver transplantation and 2.4% died of 
liver-unrelated causes (see Figure 7.1).  Five- and 10-year death/transplant rates were 7.1+0.8% and 
10.1+1.3% (all-cause) and 4.0+0.6% and 5.9+1% (liver-related) respectively, illustrated in Figure 7.2. 
 
Figure 7.1: Overall outcome Flow chart 
 
*All alive at the end of follow-up, HCC is Hepatocellular Carcinoma and HPS is Hepatopulmonary Syndrome. 
 
Figure 7.2: Overall Survival 
 
1267 Patients with AIH
1192 Alive
(Transplant-free) 






(2 HCC, 1 HPS)
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7.4.2  Baseline predictors of all-cause death (ACD) or transplantation 
There are several baseline characteristics that found to be associated with all-cause death (ACD) or 
transplant rate on univariate cox proportional hazard regression analysis which is shown in Table 
7.1. These include age, cardiac or respiratory co-morbidity, black ethnicity (see Figure 7.3), history of 
cancer, cirrhosis and decompensation at presentation. Serum parameters identified were bilirubin, 
platelets at the start of treatment and albumin at peak transaminases. Delay in diagnosis was not 
associated with ACD. 
 
On multivariate analysis (see Table 7.2) black ethnicity was associated with a 4-fold increased risk of 
AC death or transplantation. A history of cardiac or respiratory disease, cirrhosis or decompensation 
at presentation were all independently associated with a 2-fold increase in ACD or transplantation. 
Low platelets at the start of treatment were associated with reduced survival and higher bilirubin at 
peak transaminases was linked with adverse all-cause outcome. History of cancer and serum 
albumin were no longer significant on multivariate analysis.  
 





HR 95% CI P value 
Age 1267 1.03 1.01-1.05 <0.0001 
Cardiac/Respiratory disease 1267 2.28 1.37-3.81 0.002 
Cirrhosis*  1267 4.06 2.57-6.42 <0.0001 
Decompensation*  1267 4.10 2.64-6.55 <0.0001 





























Diabetes  1267 0.65 0.353-1.21 0.32 
PBC  1267 0.67 0.32-1.39 0.28 
Symptomatic  1267 0.99 0.57-1.73 0.99 
Cancer  1267 0.39 0.20-0.77 0.007 
AMA positive  1267 1.03 0.48-2.25 0.93 
Peak ALT  1110 1 0.99-1 0.218 
Bilirubin at peak transaminases  1218 1 1.001-1.004 0.004 
IgG >16g/L 877 1.02 0.544-1.95 0.931 
Low Platelets ** 1205 0.993 0.99-0.995 <0.0001 
Albumin at peak transaminases 1047 0.92 0.88-0.949 <0.0001 
Time to diagnosis 1267 1 0.99-1.02 0.89 





Figure 7.3: Cumulative survival estimation for all-cause death or transplantation for different ethnicities 
 
 
Table 7.2: Baseline parameters associated with all-cause death or transplantation (multivariate analysis) 
Parameter (no of values) HR 95% CI P value 
Age 1.03 1.01-1.05 0.002 
Cardiac/Respiratory disease 2.07 1.15-3.73 0.015 
Black ethnicity 4.37 1.17-16.25 0.028 
Cirrhosis*   2.01 1.17-3.47 0.012 
Decompensation*  2.23 1.28-3.88 0.005 
Bilirubin at peak transaminases 







*at presentation, **at start of treatment 
 
7.4.3 Baseline predictors of liver-related death (LRD) or transplantation 
Those factors found to be associated with liver-death or transplantation on univariate analysis (see 
Table 7.3) were black ethnicity, cirrhosis and decompensation at presentation. Serum parameters 
associated were low platelets at the start of treatment, high bilirubin and low albumin at peak 
transaminases. 
 
The factors independently associated (see Table 7.4) with liver-related death and transplantation 
were cirrhosis and decompensation at presentation; with a more than 3-fold and more than 2-fold 
increased risk respectively. Serum parameters associated with poor outcome were bilirubin at peak 
transaminases and low platelets at the start of treatment. Black ethnicity nor bilirubin were 
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independently associated with LRD or transplantation. Importantly delay in diagnosis was not 
associated with LRD or transplantation.  
 
Table 7.3: Baseline parameters associated with Liver-death and transplantation (Univariate analysis) 
Parameter 
 
No of values HR 95% CI P value 
Age 1267 1.01 0.987-1.02 0.60 
Cardiac/Respiratory disease 1267 0.8 0.32-2.05 0.65 
Cirrhosis*  1267 8.04 4.14-15.6 <0.0001 
Decompensation*  1267 7.11 3.81-13.26 <0.0001 































Diabetes  1267 0.95 0.37-2.39 0.88 
PBC  1267 0.62 0.25-1.58 0.32 
Symptomatic  1267 0.58 0.25-1.37 0.99 
Cancer  1267 0.82 0.25-2.65 0.74 
AMA positive  1267 0.99 0.35-2.76 0.98 
Peak ALT  1110 1.00 1.0-1.001 0.68 
Peak Bilirubin   1218 1.004 1.002-1.006 <0.0001 
IgG >16g/L 877 1.02 0.544-1.95 0.931 
Low Platelets ** 1205 0.993 0.99-0.995 <0.0001 
Albumin at peak ALT 1047 0.88 0.842-0.921 <0.0001 
Time to diagnosis 1267 0.98 0.98-1.01 0.19 
*at presentation, **at start of treatment 
 
Table 7.4: Baseline parameters associated with Liver death and transplantation (multivariate analysis) 
Parameter (no of values) HR 95% CI P value 
Cirrhosis*   3.82 1.82-8.01 <0.0001 
Decompensation*  2.65 1.28-5.46 0.008 
Peak Bilirubin   1.00 1.001-1.005 0.002 
Low Platelets ** 0.99 0.990-0.997 0.001 
*at presentation, **at start of treatment 
 
7.4.4 Treatment and outcome 
There was a wide variation of different treatment regimens initiated at the start of treatment; these 
are shown in Table 7.5. 
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Table 7.5: Initial treatment regimens 















Corticosteroid monotherapy (%) 
Corticosteroids + other agent (started ≤ 90 days) 
Corticosteroids + other agent (started >90 days-6 mo) 
Corticosteroids + other agent (started >6 mo) 
 





























There were 81 patients who did not receive drug therapy; 18 (22%) of these did achieve 
normalisation of their transaminases. Untreated patients had worse all-cause and liver related 
outcomes on univariate and multivariate analysis (all p=<0.001). This was still maintained even when 
those who had less than 3 months follow-up for ACD (univariate p=0.001 and multivariate p=0.03 
and for LRD (univariate p=0.018, on multivariate p=0.01) or transplantation. If the analysis was 
further restricted to those with >3 months follow-up and to those who were not decompensated at 
baseline, then all-cause death was significant (p=0.017) on univariate but not multivariate analysis 
(p=0.053) but not LRD (p=0.53 (univariate analysis)). 
 
Compared to treated patients (n=1186), untreated patients had lower mean (±SD) peak ALT levels; 
417±469 vs 711±646 (p=<0.001) and were less likely to be jaundiced (defined here as Bilirubin >50 
IU/L); 17(21%) vs 449(38%); p=0.002.  
7.4.4.2 Corticosteroid treatment 
Compared to those patients who received steroids (n=1175) at some point in clinical course, those 
that did not (n=92) were older: 58 vs 52 years (p=<0.001) but had similar prevalence of cardio-
respiratory comorbidity, cirrhosis and decompensation at presentation. 
 
Steroid treatment conferred significant survival benefit (p=<0.001) for both all-cause and liver-
related death/transplantation (Figure 7.4 and Figure 7.5), this is also significant on multivariate 
analysis (p=<0.001) in Table 7.6 and Table 7.7.  There was a 79% reduced risk of AC-death or 
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transplantation and an 82% reduced risk of liver-related death or transplantation if patients were 
treated with steroids. 
 
Figure 7.4: All-cause death/transplantation and steroid therapy 
 




Table 7.6:  Basic treatment factors and all-cause death or transplantation 
Parameter (no of values) Univariate Multivariate 
 HR (95% CI) AC-deaths/ 
transplantation 
P-value 
HR (95%CI) AC-deaths/ 
transplantation 
P-value 
Steroids vs no steroids (1267) 0.21 (0.12-0.37) <0.001 0.26 (0.13-0.49) <0.001 
Time to treatment *** (1186) 0.97 (0.9-1.0) 0.34 - - 
Age (1267) 
Cardiac/Respiratory ~(1267) 













Cirrhosis* (1267) 4.06 (2.6-6.4) <0.001 2.20 (1.15-3.49) 0.013 
Decompensation* (1267) 4.10 (2.6-6.6) <0.001 2.17 (1.25-3.78) 0.006 
Peak Bilirubin (1218) 1 (1.001-1.004) 0.004 1.003 (1.001-1.004) 0.004 
Low Platelets**(1205) 0.92 (0.88-0.95) <0.001 0.99 (0.99-0.996) <0.001 
*at presentation **start of treatment ***from diagnosis ~co-morbidity 
 
Table 7.7: Basic treatment factors and liver-related death or transplantation 
Parameter (no of values) Univariate Multivariate 
 
 
HR (95% CI) Liver-deaths/ 
transplantation 
P-value 
HR (95%CI) Liver-deaths/ 
transplantation 
P-value 
Steroids vs no steroids (1267) 0.18 (0.91-0.36) <0.001 0.12 (0.58-0.26) <0.001 
Time to treatment*** (1186) 0.97 (0.88-1.06) 0.46 - - 
Cirrhosis*  (1267) 8.04 (4.14-15.6) <0.001 4.07 (1.91-8.65) <0.001 
Decompensation* (1267) 7.11 (3.81-13.26) <0.001 2.17 (1.04-4.5) 0.038 
Peak Bilirubin  (1218) 1.004 (1.002-1.006) <0.001 1.0 (1.002-1.006) <0.001 
Low Platelets** (1205) 0.993 (0.99-0.995) <0.001 0.99 (0.99-0.998) 0.002 
*at presentation **start of treatment ***from diagnosis  
 
This significance persisted even after removal of patients who had less than 3 months follow-up for 
liver-related: p=0.006 but not all-cause (p=0.08) death/ transplantation. Time to treatment from 
diagnosis did not impact on liver-related survival. 
7.4.4.3 Type of Corticosteroid 
A comparison of type of steroid initially given and the baseline presenting features and outcome is 
shown in Table 7.8 (n=1169). Budesonide was used in 5% of patients at a median dose of 9mg (3-
9mg/day); 47 (81%) of these patients were initiated by University Hospital’s. Those patients 
receiving Methylprednisolone or Hydrocortisone (patient with coeliac disease) were pooled with 
Prednisolone as all were given prednisolone shortly afterwards. Those receiving prednisolone (or 
equivalent) had significantly higher serum ALT, more likely to be jaundiced, have cirrhosis and have 
decompensation at baseline (all p=<0.01). There were a similar proportion of patients with cirrhosis 
in both groups, of note 28% in the Budesonide group.  Whilst median treatment duration was longer 
in the prednisolone group compared to Budesonide, there were only 8 (of 61) patients who were 
given Budesonide before 2010 and only 3 of these were prevalent patients.  
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   Jaundice (bilirubin >50mol/L): N (%) 369 (35)€ 4 (7)€€ <0.001 
   Cirrhosis: N (%) 276 (25) 16 (28) 0.64 
   Decompensated at presentation: N (%) 245 (22) 4 (7) 0.006 
   Pre-treatment IAIHGS: median(range) 15(1-22) 14(5-22) 0.47 
   Moderate/severe Necroinflammation on biopsy: N (%)  370 (63)^ 18 (55)^^ 0.36 
   Dose at start of treatment (mg): median (range) 30 (2-60)+ 9 (3-9)++ - 
 
Outcome 










   Treatment duration: median(range), months 19 (1-241)¥ 10 (1-144)¥¥ 0.004 
   Conversion of Bud to Pred N (%) 







   Transplantation N (%) 17 (1.5) 2 (3) 0.24 
   Any Death/transplant 54 (4.8) 2 (3) 1 
*there were 20 patients; given Hydrocortisone (1) or Methylprednisolone (19) prior to prednisolone).  
ꞙAvailable in 1043 and ꞙꞙ56 patients. €Available in 1062, and €€56 patients. 
^Available in 591 patients, ^^Available in 33 patients.  +Dose unknown in 21, and ++ Dose unknown in 2 patients. 
¥Available in 1100 patents, and ¥¥ available in all patients. 
 
Overall outcome (ACD and LRD and transplantation) was not different between the two groups 
(p=0.94 and 0.5 respectively). The Kaplan Meier plot for all-cause survival and transplantation is 
shown in Figure 7.6. The Kaplan Meier survival analysis of those with and without cirrhosis in the 
Budesonide group was not statistically significant (p=0.08) but it is note that both the patients that 
required liver transplantation had cirrhosis at presentation. Of those in the Budesonide group with 
cirrhosis with ALT values available; 10/15 (67%) patients compared to those without cirrhosis 29/32 
(91%); (p=0.04) had normal ALT at 6 months (male <35 and female <30 IU/L).  
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Figure 7.6: All-cause death and transplantation and type of steroid used 
 
 
After treatment initiation, the mean 6 month serum ALT was lower in the prednisolone group (56 
±114 vs 91±280; p=0.001), but the median ALT at 6 and 12 months for prednisolone group versus 
Budesonide was no different: 31(5-2161) vs 31(13-1824) and 25(7-1149) vs 27(11-73) IU/L (p=0.08 
and p=0.3 respectively) despite higher baseline ALT levels in the prednisolone group.  There was a 
similar proportion of patients achieving normal serum ALT values after 6 (69 vs 70%; p=1) and 12 
months (85 vs 75%; p=0.2) of treatment. Three percent (2/58) of patients receiving Budesonide had 
a follow-up biopsy had new cirrhosis found in both patients (100%) versus 7% (22/316) of those 
receiving prednisolone (28% of which biopsied (316/1111)) and NIS was moderate or severe in 50% 
vs 23% respectively.  
7.4.4.4 Dose of corticosteroid 
An initial dose of prednisolone (or equivalent (methylprednisolone or hydrocortisone)) of 35mg or 
more (n=416) compared to those receiving less (n=653) was found to negatively impact and survival 
for both ACD (see Figure 7.7) and LRD and transplantation (HR 2.1 (1.24-3.55);p=0.005 and HR 2.87 
(CI 1.37-6.04); p=0.005 respectively) on univariate analysis. On multivariate analysis a dose of 35mg 
prednisolone or above was found to be an independent predictor for all-cause (HR 2.25 (CI 1.24-
4.05); p=0.007) but not for liver-related death and transplantation HR 1.99 (CI 0.90-4.43); p=0.089. 
Higher doses of prednisolone (≥35mg) were used in those with higher ALT (943 ±694 vs 580±557 
IU;p=<0.001) and higher Bilirubin (128±143 vs 65±97 µmol/L; p=<0.001) levels. There was no 
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difference in time to normalisation of ALT associated with higher doses of steroids (4.7 ±12 vs 4.6 
±11 months; p=0.92). 
 
Figure 7.7: Cumulative AC survival/transplantation and association with initial dose of prednisone  
 
7.4.4.5 Duration of corticosteroid  
Median length of steroid treatment for all follow-up times was 18(1-241) months but in those with 
at least 4 years follow-up, this increased to 31(1-241) months. Shorter duration of steroid treatment 
for all periods of follow-up was found to be an independent predictor of all-cause and liver-related 
death and transplantation (all p=<0.001). However, when restricted to the 995 patients who had 
more than one year of follow-up, it was found that continuing steroids for more than one year when 
compared to those who did not continue for one year was not detrimental to all-cause or liver death 
and transplantation (p=0.98 and 0.99 respectively).  Nor did death/transplant rates differ between 
patients who continued.  
7.4.4.6 Steroid-Sparing agents (SSA’s) 
Overall, 1053 patients received an SSA during follow-up. Patients taking steroid-sparing agents had 
improved both all-cause and liver related (LD) outcome on univariate and multivariate analysis (both 
p=<0.001). However, when removing those who had less than 6 months follow-up there was only a 
significantly improved all-cause survival (p=0.017) on univariate but not on multivariate cox 
regression analysis (p=0.95).  Liver-related outcome was not significantly affected by treatment with 
SSA’s when limited to those with more than 6 months follow-up (p=0.58 on univariate analysis).  
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When comparing those patients who were initially given steroids alone (n=148) compared to SSA 
alone (n=19) and also with SSA plus steroids (n=1019), there was a significant improvement in both 
all-cause and liver related survival and transplantation in the combined therapy group as shown in 
Figure 7.8 and Figure 7.9 (p=<0.001 and p=0.001 respectively).   
 
Figure 7.8: SSA and steroid groups and association with all-cause death/transplant 
 
Figure 7.9: SSA and steroid groups and association with Liver-related death/ transplant 
 
On multivariate analysis there was a more than 3-fold increased risk of death between the steroid 
alone group compared with the combined therapy group for both AC and LRD or transplantation (HR 
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3.09 (CI 1.69-5.66):p=<0.001 and HR 3.59 (CI1.61-7.98); p=0.002 respectively). However, when those 
with less than 3 months follow-up were excluded, this relationship was lost (p=0.16 and p-=0.68 on 
univariate analysis). The median timing of SSA initiation was 1.4 (0-132) months and delay in 
receiving an SSA did not affect outcome (ACD; p=0.472 and LRD; p=0.609). 
 
Of the three main types of SSA given first; Mycophenolate (n=32) had significantly superior survival 
compared to Tacrolimus (n=10) for LRD (see Figure 7.10; p=<0.001) and ACD and transplant 
(p=0.014), but not when compared to Thiopurines alone (LRD: p=0.43and ACD: p=0.26). 
Cyclosporine, Cyclophosphamide and Methotrexate were given to a total of only 3 patients, thus 
were excluded from this analysis. Tacrolimus was compared to other SSA’s used in younger patients 
(40(±16) vs 51(±17); p=0.028, with more severe disease; mean (±SD) bilirubin 230(±232) vs 86(±116); 
p=0.0003, and in those with cirrhosis 7/10(70%) vs 263/1043(25%); p=0.0012. Eight of these ten 
patients did go on to normalise their transaminases but one died from liver failure and one 
underwent liver transplantation. However, on multivariate analysis with baseline predictors of 
outcome, the type of SSA was no longer significantly associated with either LRD or ACD or transplant 
(p=0.21 and 0.65 respectively). When those with less than 3 months of follow-up were excluded 
then significance on univariate analysis was also lost for both LRD and ACD or transplant. 
 
Figure 7.10: Type of SSA and association with liver-related death and transplant 
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7.4.5  Treatment response 
Of all 1186 treated patients; 1098 (93%) eventually achieved normalisation of their transaminases. 
The median time to normalise transaminases was 2 (0-135) months (the number of patients where 
the time was known was 1025).  There were 1013 treated patients who had more than 6 months 
follow-up and had dates of ALT normalisation, with 34 of these normalising prior to the start of 
treatment. There were 818 (of 979 (84%)) who normalised ALT by 6 months. 
 
Failure to normalise transaminases for the duration of follow-up was found to be significantly 
associated with death (AC and LD) and decompensation occurring at presentation (all p=<0.001). In 
contrast, failure to achieve ALT normalisation at specific time points (at 28 days, 6 months and at 12 
months) showed no association with ACD or LRD /transplantation (all p=>0.05), with or without 
treatment. However, the value of ALT at 28 days and 3 months (significant on univariate analysis in 
Table 7.9) was found to be an independent predictor of outcome for LRD or transplantation on 
multivariate analysis with baseline predictors (HR 1.002 (CI 1.001-1.004); p=0.003 and HR 1.003 (CI 
1.001-1.005); p=0.009 respectively) and also at 28 days a predictor for ACD (HR1.002 (CI 1.001-
1.003); p=0.003).  
 
Table 7.9:  ALT value at specific time points and outcome (univariate analysis) 
ALT at Time 
(no of values) 
Any death/transplant 






HR (95% CI) 
p-value 
 
7 days (n=649) 
28 days (n=860) 
3 mo (n=846) 
6 mo (n=840) 






















Of the patients who received treatment and achieved normal transaminases (n=1098); 306 (28%) 
had a follow-up liver biopsy. There were 97 (39%) had no or minimal inflammation on Ishak scoring 
(251 had necroinflammatory scores). 
7.4.6 Drug Toxicity 
Corticosteroids 
Of those treated with corticosteroids (n=1175); 151 (13%) patients suffered ≥1 more steroid side 
effects. Specifically, steroid psychosis occurred in 14 (1%) after a median (range) of 2(1-16) months 
on treatment, receiving a median initial dose of 30(20-40mg) Prednisolone. Low trauma fracture was 
reported in 5 (0.4%) at a median of 30(1-72) months.  Diabetes was diagnosed in 53 (4.5%) patients 
during treatment; receiving a median initial dose of 40(20-60mg) Prednisolone with median length 
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of treatment of 5(1-94) months. Where dose was known, those who were given a prednisolone dose 
of 35mg or more (n=416) were found to have a higher incidence of diabetes development during 
follow-up (27 (6.5%) vs 23 (3.5%)); p=0.025 on chi square) than those who received less (n=653).  
Compared with Prednisolone, Budesonide had less reported side effects (13% vs 3%: p=0.02), with 
no steroid psychosis, diabetes or low trauma fracture, and only two patients (3%) having any 
documented side effects (weight gain and ‘generally unwell’). 
 
Steroid-Sparing agents (SSA’s) 
Of 1053 patients receiving a SSA; 31% (316/1015) patients reported Azathioprine side effects; the 
commonest being leucopenia (white cell count <2.5 and fall of >1.0) in 64 (6%) patients at median of 
8 (1-96) months) and 3 (0.3%) patients got pancreatitis (all Azathioprine) at a median of 2 (1-18) 




Of a total of 52 patients receiving Tacrolimus; 5 (10%) patients had side effects including headaches, 
tremor, pneumonia and diarrhoea.  
 
7.4.7  Maintenance of normal transaminases, relapse and association with 
outcome 
Of those who achieved normal transaminases, 538 (49%) maintained normal values throughout 
follow-up.  
 
Of 1098 patients who were treated and achieved normal transaminases there were 354 (32%) 
patients who relapsed (transaminases >2 times the upper limit of normal (ULN)), of which 61 had 
cirrhosis. During the first relapse there were 316 where ALT was known (the rest had a documented 
AST instead) and 138/316 (44%) had ALT ≥5 times the ULN (35IU/L defined as ULN for ALT) and 18 
(5%) (of 342 where values known) were jaundiced (bilirubin >40). The first relapse occurred a 
median of 12 (0-138) months from date of first normalisation. There were 134 (12) who had 2 
relapses and 54 (5%) who had ≥3 relapses. 
 
The baseline parameters associated with relapse were age, cirrhosis and decompensation at 
presentation on univariate binary logistic regression analysis (see Table 7.10). On multivariate 
analysis (see Table 7.11) the patients are less likely to have a relapse if they are of older age at 
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diagnosis and patients are 42% less likely to have a relapse if they have cirrhosis at baseline (OR 0.58 
(CI 0.42-0.80); p=0.001). 
 
Having a one or more relapses was found to improve AC-survival and transplantation (HR 0.27 (CI 
0.09-0.88); p=0.03) on univariate analysis but not on multivariate analysis HR 0.55 (0.17-1.82); 
p=0.33. However, one or more relapses had no effect on liver-related mortality or transplantation on 
univariate analysis (p=0.08 and p=0.09 respectively). When those with less than 6 months of follow-
up are removed, then there is no significant association on ACD or LRD on univariate analysis with 
number of relapses (all p=>0.05). 
 
Table 7.10:  Baseline Parameters and association to relapse (univariate analysis) 
Baseline Parameter OR (95% CI) P Value 
Female gender 0.95  (0.8-1.1) 0.48 
Age at diagnosis 0.98 (0.97-0.99) <0.001 
Black ethnicity 0.61 (0.13-2.9) 0.54 
Cardiac/Respiratory comorbidity 0.99 (0.69-1.41) 0.95 
Peak ALT 1.0 0.21 
Albumin (<35g/L) 1.002 (0.75-1.33) 0.99 
IgG at peak ALT (>16g/L) 0.74 (0.52-1.04) 0.084 
Bilirubin (>150µmol/L) 1.08 (0.81-1.43) 0.62 
Platelets <150U/L) 0.74 (0.52-1.04) 0.084 
Cirrhosis at presentation 0.54 (0.39-0.74) <0.001 
Subsequent cirrhosis 1.24 (0.74-2.06) 0.41 
Decompensation at presentation 1.53 (0.79-2.96) 0.025 
Prednisolone initial dose ≥35mg 0.98 (0.75-1.23) 0.88 
 
Table 7.11: Baseline Parameters and association to relapse (multivariate analysis) 
Baseline Parameter OR (95% CI) P Value 
Age at diagnosis 0.98 (0.977-0.992) <0.001 
Cirrhosis at presentation 0.58 (0.42-0.80) 0.001 
 
7.4.8  Disease Progression 
During clinical follow-up; de-novo cirrhosis developed in 76 of 949 (8%). This was confirmed 
histologically in 25 (33%), and by the presence of varices or variceal bleed, encephalopathy, 
ascites/oedema, on imaging or Fibroscan scores consistent with cirrhosis (7 by fibroscan alone). 
Median time to de-novo cirrhosis was 15 (1-140) months. All but one of these patients had a prior 
baseline biopsy and all but one (not clear) of these reports stated they did not have cirrhosis (Ishak 
fibrosis score was available in 39 (all ≤4)). 
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The baseline parameters associated with de-novo cirrhosis are shown in Table 7.12. Multiple 
relapses compared to those with just one relapse were associated with a 3-fold increased likelihood 
of developing cirrhosis. Low platelets and low serum albumin at baseline were associated with a 6-
fold and two and a half-fold increase risk of developing cirrhosis during follow-up (Table 7.13). 
 
Table 7.12: Baseline factors associated with subsequent development of cirrhosis during follow-up 
Parameter 
 
No of values OR 95% CI P value 
Age 949 1.008 0.99-1.02 0.26 
Gender (Female) 949 0.68 0.53-0.88 0.003 
Black ethnicity 949 0 - 0.99 
AMA positive  949 0.77 0.33-1.83 0.56 
Symptomatic  949 1.75 0.90-3.3 0.97 
Peak ALT  829 1.00 1.0-1.0 0.88 
Peak Bilirubin >150µmol/L 906 1.39 0.85-2.28 NS 
IgG >16g/L 651 1.63 0.80-3.29 0.18 
Platelets <150U/L* 899 3.59 2.11-6.12 <0.0001 
Albumin at peak ALT <35g/L 779 3.83 2.28-6.46 <0.001 
Transaminase normalisation 949 0.91 0.38-2.17 0.83 
Relapse 949 1.05 0.64-1.76 0.83 
Multiple versus one relapse 304 3.04 1.3-7.12 0.011 
 
Table 7.13: Baseline factors associated with de-novo cirrhosis during follow-up (multivariate analysis) 
Parameter OR (95% CI) P Value 
Gender 0.87 (0.51-1.49) 0.158 
Platelets <150U/L 6.43 (2.36-17.52) <0.001 
Albumin at peak ALT <35g/L 2.61 (1.04-6.58) 0.042 
Multiple versus one relapse 3.19 (1.24-8.21) 0.016 
 
There was also an increased risk of adverse outcome if cirrhosis developed during follow-up 
(p<0.001 for ACD and LRD or transplantation). Those who developed de-novo cirrhosis during follow 
up had a 2-fold increase risk of ACD or transplantation (HR 2.40 (1.03-5.55); p=0.042) and a 9-fold 
increased risk of LRD or transplantation on multivariate analysis (HR 9.37 (CI 2.76-31.8); p= <0.001). 
 
Development of new clinical decompensation (Ascites/oedema, variceal bleed or encephalopathy) 
or hepatopulmonary syndrome developed in 49 (3.9%) patients at a median time of 33(1-137) 
months. The total number with clinical decompensation at any time was 150 (12%). Variceal 
bleeding occurred in 18 (1.4%) at a median of 6(0-11) months during follow-up. 
 
Hepatocellular carcinoma occurred in 7 (0.6%) patients at 43(15-128) months after diagnosis; one 
died, 2 patients underwent liver transplantation, four were still alive and transplant free (all 79 yrs 
old or older) and underwent resection or palliative treatment. 
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Hepatopulmonary syndrome occurred in 3 patients at 46(7-52) months; one patient underwent 
transplantation, one was being assessed at time of data collection.  
7.4.9 Type of Hospital and outcome 
There were 437 patients attending DGH’s and 830 patients attending UH’s. Compared to DGH’s 
patients attending UH’s were more likely to be treated with steroids 393 (90%) vs 782 (94%); 
p=0.005, and more likely to receive Budesonide 12/392 (3%) vs 49/780 (6%); p=0.019. 
 
Patients were more likely to receive an SSA 719 (87%) vs 334 (76%);p=<0.001 and less of a delay in 
initiating an SSA (<3months) 177 (25%) vs 124 (37%) if attending UH’s compared to DGH’s. 
 
Patients attending UH’s also had lower mean serum ALT levels at 3 months (65 ±104 vs 100±181; 
p=<0.001) and were more likely to attain normal levels at 3 months (41% vs 34%; p=0.03), 6 months 
(54% vs 45%; p=0.019) and 12 months (64% vs 55%; p=0.02) than those attending DGH’s. 
 
Whether patients attended District General hospitals (DGH’s) or University Hospitals (UH’s) did not 
affect overall outcome; for AC: p=0.13 and LRD: p=0.017 death/transplantation on univariate 
analysis. On multivariate analysis (Table 7.14) DGH/UH status was not significantly associated with 
LRD or transplantation (p=0.09). 
 
Table 7.14: Type of Hospital and liver death or transplantation (multivariate analysis) 
Parameter HR 95% CI P value 
Cirrhosis*   3.72 1.76-7.88 0.001 
Decompensation*  0.38 0.18-0.77 0.008 
Peak Bilirubin  1.00 1.00-1.005 0.004 
Low Platelets ** 








In this study we found that overall 10-year all-cause survival of 90% is slightly better than expected 
when compared to single centre UK cohorts (83-85%), 23,111 but not dissimilar to other multi-centre 
cohorts from Denmark, Sweden and Holland (74-88%), 12,14,172 although one factor that may account 
for this is that the median follow-up time in our study was shorter than others (3.8 years compared 
to 5.9-18.7). We also have to accept that not every centre may have been able to fully utilise the 
capture strategy as described. The 6% 10-year liver-related deaths and transplantation rate found in 
this study were slightly less than in other multicentre studies (7-10%)12,14,172 and other UK cohorts 
23,111 but matched a study of a whole geographical area of Canterbury, in New Zealand. 26 
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Other studies, like this one have found factors found to be linked to all-cause mortality have 
included age.14,23,111 Cirrhosis or decompensation at presentation has also been linked to both 
adverse all-cause and liver-related mortality,109,111,168,172,182 and this is corroborated in the present 
study. Cardiac or respiratory comorbidity was found to increase all-cause outcome 2-fold, and other 
groups have factored this in using co-morbidity indices (HR 1.6 (CI 1.34-1.82).14 
 
Black ethnicity has been shown by one other group to be linked to poor all-cause outcome. 21 Two 
other groups have investigated whether black ethnicity affected liver-related outcome, the first 
found outcome to be similar, 194 but the second collaborative study found poorer outcome (HR 2.4 
(CI 1.4-4.0; P < 0.001).195 Although this study found that black race was an independent predictor of 
all-cause death, it was found that adverse liver-related outcome and incomplete normalisation was 
more likely in black patients compared to non-blacks on univariate but not multivariate analysis. 
 
Serum markers at baseline that were associated with both all-cause and liver related adverse 
outcome were found to be bilirubin at peak transaminases and low platelets at the start of 
treatment, with bilirubin being a surrogate marker of disease severity and the latter likely marker of 
underlying cirrhosis. Important non-associations were established, being that neither gender, 
presence of symptoms, coexistence of PBC, delay nor time to diagnosis were related to ACD or LRD 
or transplantation. 
 
Those who remained untreated had reduced survival. An analysis of the proportion of patients with 
jaundice and mean ALT in treated group compared to the untreated group reveal that the clinicians’ 
decision to treat may have been based influenced by these parameters. However, the untreated 
group seemed to harbour some patients who were entering acute or sub-acute liver failure, in whom 
it may be contentious to immunosuppress, and appropriately underwent early liver transplantation. 
The sub-analysis excluding early deaths showed that those left untreated still had reduced all-cause 
and liver-related survival which indicates that these patients would have benefited from treatment. 
Even with further sub-analysis, in those with more than 3 months follow-up and those 
decompensated at baseline were removed, this was still significant for AC survival, but unsurprisingly 
not for liver-deaths underlining the potential advantage of treatment.  
 
Our results show that patient’s not receiving corticosteroid therapy had inferior ACD and LRD or 
transplantation outcome. The decision not to treat may have been influenced by older age. The sub-
analysis confined to patients who had more than 3 months follow-up (thereby excluding early 
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deaths) still showed an adverse outcome in patients not treated with steroids indicating that leaving 
these patients untreated is not justified.  
 
There appeared to be wide variation of length of steroid treatment and our observation that shorter 
duration was linked to adverse outcome is probably related to follow-up time, which of course itself 
is interrelated with outcome, thus may be an artefactual finding. When restricting analysis to those 
with more than 12 months follow-up, outcomes were similar in those continuing treatment for more 
than 12 months compared to those who did not. This means this study could not confirm that 
duration of steroid treatment is related to improved outcome. Although, because of the median 
follow-up time it was not possible to analyse longer-term outcomes effectively but there remains 
the possibility that histological remission may be more likely achieved with longer durations of 
steroid therapy. 
 
Whether patients initially received Prednisolone or Budesonide was not associated with ACD or LRD 
or transplantation. Although Budesonide has been shown in randomised controlled trials to achieve 
a greater rate of ALT normalisation 105,196-198 than Prednisolone there are few data on its longer-term 
efficacy, with only one study reporting up to 2-year remission rates199 and none on histological 
remission or 5- and 10-year survival. This study shows here that despite this, Budesonide is being 
used in secondary care as a first line treatment for AIH in 5% of patients. Compared to those initially 
receiving Prednisolone, those receiving Budesonide had similar age and gender distribution but had 
less severe liver dysfunction and more likely to be attending University Hospitals. Interestingly, there 
were a similar proportion of patients with cirrhosis in each group. Of concern 28% of patients who 
received Budesonide had cirrhosis, including the two patients who later required liver 
transplantation. This is somewhat surprising when the presence of cirrhosis is a contraindication for 
Budesonide use given the 90% reduced hepatic metabolism and portosystemic shunting giving rise 
to side effects and also its association with venous thrombosis. 200 This is especially important given 
that Budesonide is also associated with reduced efficacy in cirrhosis.201  This may explain why the 
overall mean 6 month ALT (but not median) was lower in the patients given Prednisolone rather 
than Budesonide and why those with cirrhosis in the Budesonide group compared to those without 
had a significantly lower proportion achieving ALT normalisation at 6 months despite the higher 
baseline serum ALT.  However, it is accepted that there were fewer patients in the Budesonide group 
to make comparisons. Treatment duration was longer in the prednisolone group, this probably 
relates to Budesonide not being used frequently before 2010, this coincides with the publication of 
the largest randomised control trial in AIH (Published in October 2010), comparing Budesonide and 
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prednisolone, with the primary endpoint being biochemical remission without side effects.105 
Contrary to this study and others196-198 this study found no difference in ability to normalise ALT at 6 
months, although our study is an audit, it is an important observation that these patients appear to 
have similar biochemical outcomes. Only two patients receiving Budesonide had a follow-up biopsy 
but both patients had developed cirrhosis during follow-up, these are too few to draw any 
conclusions but does perhaps highlight that there are no data published on histological remission 
rates or cirrhosis development in these patients. It is well known that Budesonide has a superior side 
effect profile which is echoed here. 105,199 
 
Dosage of corticosteroids equal to or above 35mg of prednisolone was fascinatingly linked to 
reduced all-cause survival, presumably due to their metabolic effects and increased risk of ischaemic 
heart disease. This is analogous to a recent study in patients with Rheumatoid arthritis where there 
was found to be a dose-dependent increase in all-cause mortality.202 New onset diabetes during 
follow-up was 5% and was significantly associated with the higher dosage of steroids (≥35mg), which 
also must be more commonly prescribed by our European and American counterparts, given their 
dosing guidance.  2,86 Selecting a higher dose of steroids appeared to be linked to the degree of ALT 
and bilirubin elevation.  
 
Treatment with steroid-sparing agents have been found to allow reduction in corticosteroid dosage, 
maintain remission and prevent relapse.100,129 SSA’s were only shown to reduce all-cause and liver 
related outcomes when considering all periods of follow-up, but do not significantly affect ACD or 
LRD or transplantation outcomes when early follow-up events are removed, implying an ‘early 
effect’ on mortality only. Although there was a wide variation in timing of SSA initiation, this did not 
affect outcome. This study observed superior outcome in those initially receiving mycophenolate 
compared to other agents, it is well known that this is the preferred agent in those intolerant but not 
unresponsive to azathioprine.141 Azathioprine was associated with side effects in approximately one-
third of patients but only 5% had adverse effects with mycophenolate. Despite its cost still it is 
established as a good option for the approximately 16% of patients that discontinue Azathioprine,203 
but there is importantly the currently on-going CAMARO trial (ClinicalTrials.gov) comparing standard 
therapy (steroid plus azathioprine) versus steroid plus MMF for treatment naïve patients and 
anticipate that this will formally answer this question.  
 
Those receiving tacrolimus first-line were younger patients with more severe disease, and although 
had a high proportion of early deaths, longer-term outcome was not affected.  The incidence of side 
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effects with tacrolimus in other studies of AIH are between 16-30%,204,205 which is higher than in our 
cohort. 
 
As well as increased age, the factors associated with treatment response at 6 months were low 
platelet level and cirrhosis at presentation, whilst this study found a 57% and 48% reduced likelihood 
of having a normal ALT by 6 months, this is contrary to a report from one single centre; where no 
significant relationship was found, but there was an association with low platelet level. 26 However, a 
more recent study, including more patients also found, like this study, that  cirrhosis was associated 
with attainment of remission.167 
 
Only just over one-third of patients were in histological remission on follow-up biopsy despite 
normalising transaminases.  It is perhaps relevant that time in remission and serum ALT on the day 
of biopsy was not evaluated, which may have influenced interpretation histological remission lags 
behind biochemical remission as.  Histological remission is however, important because it has been 
linked with both all-cause and liver related adverse outcome. 117  
 
Like some, 127,182,206 but not all,206 this study found younger age to be linked  to relapse.  However, 
the present study found cirrhosis at presentation was associated with a reduced likelihood of relapse 
but other studies have found no association but many of these were in the context of treatment 
withdrawal. 127,207,208 It is unclear why this is the case but adherence to treatment specifically was not 
assessed and one postulates that this could be a confounding factor in these groups. Multiple 
relapses compared to patients having one or zero relapses was associated with the development of 
de-novo cirrhosis corroborating others findings, although this data did not observe an effect on 
mortality as others have found, which may be due to this cohorts median follow-up time.23,172 
 
Subsequent cirrhosis development during follow-up independently predicted poor outcome (all-
cause and liver-related) was similar to others findings.23,172 Male gender, low platelets and low serum 
albumin at diagnosis were associated with an increased risk of developing de-novo cirrhosis. The 
latter two parameters are unsurprising but raise the question as to whether the patients had 
cirrhosis at baseline, despite reassuring liver biopsies. The impact of gender on overall outcome has 
been investigated by one other UK centre but they did not examine whether gender had any 
association with de-novo cirrhosis. 111  
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Although there was an observed variation in treatment strategies for patients attending DGH’s, 
namely a reduced likelihood of receiving corticosteroid therapy, less likely to receive Budesonide or 
SSA’s and a delay in SSA initiation, there was no impact on overall mortality.   
7.6 Conclusions 
In this considerably large cohort of patients with AIH, which is probably representative of AIH, 
demographics which were independent predictors of all-cause mortality include age, black ethnicity 
and co-morbidity. Serum bilirubin and platelets and markers of disease severity such as cirrhosis or 
decompensation at presentation predicted both all-cause and liver-related mortality or 
transplantation. This can be taken into consideration when clinically treating these patients. Overall 
all-cause and liver-related outcome is marginally better than might be expected in this large multi-
centre cohort with the only limitations of this data being the probable incomplete capture and the 
shorter median length of follow-up than other studies. 
 
Failure to receive corticosteroids and failure to receive SSA are independently associated with 
adverse outcome which underlines their usefulness in the clinical treatment of AIH. Given the finding 
that even when early events are excluded those not receiving steroids had a higher risk of liver-
related mortality and transplantation, where reasoning is unclear, these results underline the point 
that in the absence of contraindications (sepsis or uncontrolled diabetes; which are treatable and 
usually temporary) corticosteroids should always be offered to patients with AIH. 
 
Initially high dosages of prednisolone used in treatment of AIH have a 2-fold increased risk of all-
cause death or transplantation and is associated with development of diabetes, therefore caution 
should be used when considering dosing regimens.  
 
Type of steroid used does not affect overall outcome, although needs to be carefully interpreted in 
this cohort as it tended to be used in less severe disease.  Budesonide was used in 5% of patients 
receiving steroids and was commonly used in patients with cirrhosis and although numbers were 
small, these patients did not achieve normal ALT’s at 6 months as often which supports its reduced 
efficacy in this cohort and thus emphasises the lack of evidence for its use in these patients. 
 
Increased age was positively associated with achieving normal ALT at 6 months, whereas cirrhosis 
and low platelets at baseline associated with reduced likelihood of attaining complete biochemical 
remission. Unlike other studies relapse was not an independent predictor of outcome. 23,171,172 De-
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novo cirrhosis independently predicted poor outcome but another new finding was that male 
gender, as well as low platelets and low albumin were associated with its development. 
 
Serum ALT at 28 days and at 3 months was independently predictive of LRD or transplant and for 
ACD/transplant only 28 day ALT, so this could be used as a prognosticator in clinical practice. Despite 
guidelines suggesting that steroids should continue for one to two years we found there to be a lack 
of evidence for long duration of steroids. 
 
We observed differences in treatment strategies between those attending DGH’s and UH’s and 
although patients have similar outcome they appear to be treated less often with steroids and SSA’s 
and do not normalise ALT levels as quickly. The impact of this on longer-term outcome is at this 
point unknown but one hopes that dissemination of this information will lead to improvement in 
standards of care in these hospitals. 
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Chapter 8: Provision and standards of care for treatment and follow-
up of patients with Autoimmune Hepatitis- UK multicentre Audit 
8.1 Introduction 
Although considered a rare disease, AIH has a prevalence and incidence in Western Europe of 
24/100,000 and 1.7/100,000 respectively, 8,12,14  equivalent to a UK District General Hospital serving 
approximately 250,000 people, having about 60 patients with AIH attending it, and seeing 4-5 new 
patients per year.  AIH is usually a life-long disease, which even with standard treatment can result in 
progressive liver disease and excess mortality.23,112,113 AIH is thus a substantial health burden in the 
UK but there is variation in care, facilities and in opinion regarding management. 164,175,209 
Here, we report on the available resources and on adherence to the pre-agreed management 
standards in participating centres.  
8.2 Aim 
To undertake an Audit of service provision for and care of AIH in 28 UK hospitals.  
8.3 Methods: 
We arrived at our audit standards based on the 2012 meeting and on the (then) recently published 
AASLD and BSG Guidelines,1,86 and these are detailed in Chapter 1 and in Table 1.2. 
 
Audit design, conduct, case capture and validation are discussed in detail in earlier chapters 
(Chapters 2, 3, 4 and 5). Centres provided information about staffing, infrastructure and patient 
management via the encrypted web-based data collection tool (See Appendix A and C).  
 
Results, unless stated otherwise, are expressed as median (range). Z test was used to calculate 
proportional differences and Mann-Whitney U test used for non-parametric independent samples. 
p<0.05 was considered statistically significant. 
 
Hepatologists were defined as consultants with >70% of their workload being liver disease. 






Of 28 centres, 14 classified themselves as District General Hospitals (DGH’s); 9 with >500 beds, and 
14 as University Hospitals (UH’s); all with >500 beds. Sixteen hospitals accepted Hepatology referrals 
from other hospitals. 
 
Hospitals had a median (range) of 8(3-23) Consultant Gastroenterologists.  Of these, 3(0-10) were 
Hepatologists, and more prevalent in UH’s than DGH’s (Table 8.1).  There were 0(0-4) 
Gastroenterologists per hospital who had an interest in Hepatology (GIH) and these were more 
prevalent in DGH’s. 
 
Table 8.1: Staffing and infrastructure 



















DGH (n=14) 0(0-2) 1(0-4) 2(0-4) 0.5(0-3) 35 57 
UH (n=14) 3(1-10) 0(0-3) 6(2-16) 2.5(0-7) 86 86 
P value <0.001 0.04 <0.001 0.002 0.006 0.09 
 
Eight hospitals (29%), all DGHs, had no Hepatologist and three (11%) had neither a Hepatologist nor 
a GIH (Figure 8.1). Across all hospitals, the number of Consultant Gastroenterologists who managed 
patients with AIH per hospital was 3(0-10) with only 30% having an interest in Hepatology, and the 
number of Hepatologists managing AIH was 2(0-10). Overall, 18% (n=234) of patients were being 
managed in a hospital without a Hepatologist.  
 






No Hepatologist (all DGH's)




The percentage of all the Consultants in each hospital who managed AIH was 50(18-100%). This was 
higher in DGH’s than in UH’s: 92(20-100%) vs 46(17-100%); p=0.051 (two-tailed Mann-Whitney U 
test). In eight hospitals all of the resident Gastroenterologists and Hepatologists managed AIH. 
 
Nineteen hospitals (68%) had 1(1-7) specialist nurse’s managing mainly liver disease and 9 hospitals 
(7 were DGH’s) had no liver nurses (Figure 8.2).  However, in only five (18%) hospitals (2 DGH’s) did 
specialist nurses see patients with AIH.  
 
Figure 8.2: Specialist nurse provision 
 
 
Seventeen hospitals (61%) had at least one Histopathologist with an interest in liver disease. There 
was a significantly higher proportion of these in UH’s (Table 8.1).  These specialists were more likely 
to report rosettes on liver biopsy (172/834 (21%) versus 50/378 (13%); p=0.002). 20 hospitals (71%) 
had a joint clinical-pathological meeting, with a higher proportion of meetings occurring in UH’s 
(Table 8.1).  
 
Thirteen hospitals (46%) indicated that they provided hospital patient information sheets and four 
(14%) had departmental guidelines for the management of AIH.  Ten (36%) had a pre-existing 




Liver Specialist Nurse not seeing AIH
Nurse & sees AIH
No Liver Nurse
64% of centres provide telephone advice
112 
8.4.2 Standards 
8.4.2.1 Overall cohort 
We included 1267 patient cases of AIH, with a median follow-up of 3.8(0-15) years. A summary of 
the results of performance against agreed audit standards (a-h) are shown in Table 8.2.  
 
Table 8.2: Performance against standards in the overall cohort 





% in individual 
centres 
(median(range) 
No of Centres 
meeting 
standard (%) 
Treatment     
a)  ≥90% of symptomatic patients start 
prednisolone~ within 4 months of diagnosis 
 
92 ✓ 92 (33-100) 19 (68) 
b) ≥90% steroids continued ≥1 year 73  78 (33-92) 
 
3 (11) 
c) ≥80% appropriate blood monitoring+ 74  
 
79 (3-100) 14 (50) 
d) ≥90% attain normal serum ALT by 1 year 








e) ≥80% clinically decompensated patients¥ 
who did not improve on treatment were 











    
f) ≥60% of those re-biopsied attain 
histological remission   
37  
 
35 (0-70) 2 (8)^ 
 










h) <21% new decompensation¥  7 ✓ 3 (0-10) 28 (100) 
~or equivalent (Budesonide/methylprednisolone or hydrocortisone). 
+Liver Blood tests documented at 3, 6 & 12 months adjusted for length of follow-up for the first year. 
**In those with ≥12months follow up after treatment started & date of first normal ALT is known. 
¥Ascites, encephalopathy or variceal bleed. 
^25 of 28 centres had decompensated patients or performed follow-up liver biopsies. 
 
The median time to treatment from diagnosis (defined as date of liver biopsy) in patients 
symptomatic at presentation was 0(0-92) months. Fifty-nine of 877 (7%) symptomatic patients were 
not treated with prednisolone or its equivalent, within four months (Standard a). The reasons why 
are shown in Figure 8.3. 
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Figure 8.3: Reasons why patients were not treated within 4 months of presenting symptoms 
 
*Patient wishes or obesity, ~clinician determined 
 
Of the 955 patients who received steroids (duration known) and who were followed up for at least 
12 months, steroids were continued for less than 12 months in 259 patients (failing to meet 
Standard b). The reasons are shown in Figure 8.4. In those patients stopping steroids for uncertain 
reasons; 138 of 189 (73%) had normalised transaminases within a median 1(0-9) months. Of 236 
cases (where steroid duration known), 49 (21%) had not normalised their ALT prior to stopping. 
 



























Monitoring of liver blood tests (defined as checked and recorded after 3, 6 and 12 months on 
treatment was inadequate in 26% of patients (failing to meet Standard c), with 50% of hospitals 
failing to meet the standard of ≥80% of patients with adequate monitoring, and three hospitals 
achieving adequate monitoring in less than 10% of their patients. 
 
Of 973 patients followed up for at least 12 months, and in whom date of first normal ALT was 
known, 134 (14%) did not achieve normal serum ALT by 1 year after starting treatment (failing to 
meet Standard d). Only 10 of the 28 centres met the 90% standard and in 2 (7%) centres the 
percentage was less than 50%.   
 
Standard e: ‘Decompensated cases were discussed with transplant team, where appropriate’, was 
met in the cohort as a whole. Of 150 (12%) patients who were clinically decompensated 
(ascites/oedema, variceal bleed or encephalopathy) either at presentation, or during follow-up; 45 
(30%) cases were discussed with or referred to a transplant team. A total of 105 cases were not 
discussed and there are additional data presented in Table 8.3 which demonstrate the demographic 
details of patients; 57 (38%) had significant co-morbidities and 6 (4%) were non-compliant or had 
excess alcohol consumption. There were 42 (28%) in whom there was no stated reason for non-
referral. Of these, seven patients did not improve on treatment: One of whom who had 
decompensation at presentation died of liver failure and a further six developed decompensation 
whilst on treatment; one of whom died from liver failure. Of the remaining 35 patients, one patient 
died from non-liver causes and four did not achieve normal serum transaminases (although serum 
but bilirubin normalised and albumin was normal or increasing on treatment) and the remaining 30 
remaining patients normalised transaminases (only one patient had minimally elevated bilirubin at 
47) indicating improvement on treatment. 
 
Table 8.3: Characteristics of patients not referred to transplant team (n=105) 







Alcohol excess Reason 
unknown 
Not referred 26 31 4 2 42 
 
Of 333 patients who underwent a follow-up liver biopsy, 103 (37%) of 282 patient cases (where 
necroinflammatory score recorded) were in remission (NIS ≤ 3) with wide variation between centres 
median 35% (0-70) rates of remission (Standard f). 
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Only 8% of patients developed new cirrhosis during follow-up, with all centres meeting standard h. 
Only 7 percent of patients developed liver decompensation during follow-up, meeting standard in all 
centres (Standard g). 
8.4.2.2 Sub-group comparisons and attainment of standards: 
Patients were more likely to receive SSAs for >2 years in the 14 UHs, compared to those attending 
the 14 DGHs (Table 8.4). This difference was also seen in hospitals with a Specialist Liver Nurse 
(n=23), in those with a Hepatologist (n=19), and those hospitals with complete case capture (n=4) 
achieved14 (compared to those without) (Table 8.5, Table 8.6 and Table 8.7 respectively). Patients 
attending a hospital with a Specialist Liver nurse also received steroids for longer; (82 vs 77%; 
p=0.001) (Table 8.5). Hospitals without a Hepatologist and those without complete case capture 
were less likely to have blood monitoring (69% vs 75%; p=0.04 and 69% vs 86%; p=<0.001.  However, 
there were no other differences between these different types of hospitals in regard to meeting of 
standards. 
 
Table 8.4: Standards in University hospitals (n=830 cases) versus District General Hospitals (n=437 cases) 









a)   ≥90% of symptomatic patients 
start prednisolone~ within 4 months of 
diagnosis  
 
540/593 (95) ✓ 258/284 (91) ✓ 0.9 
b)  ≥90% Steroids continued ≥1 year* 
 
495/658 (75)  250/341 (73)  0.51 
c)  ≥80% adequate blood monitoring++ 
 
560/744 (75)  280/389 (72)  0.23 
d)  ≥90% attain normal serum ALT at 1 
year treatment** 
 
598/716 (84)  281/360 (78)  0.02 
e)  ≥80% clinically decompensated 
patients¥ who did not improve on 
treatment were discussed with a 
transplant team 
 
103/108 (95) ✓ 40/42 (95) ✓ 0.97 
f)  ≥60% of those re-biopsied attain 
histological remission***   
 
69/195 (35)  34/74 (46)  0.11 
g)  ≥75% do not develop de-novo 
cirrhosis  
 
571/617 (93) ✓ 308/334 (92) ✓ 0.89 
h)  ≤21% new clinical decompensation 
 
32/754 (4) ✓ 10/405 (2.5) ✓ 0.12 
~or equivalent (Budesonide/methylprednisolone/hydrocortisone) as proportion of symptomatic patients. 
*In those followed up ≥1 year.  
+Liver Blood tests documented at 3 months, 6 months & 12 months adjusted for length of follow-up. 
***In those with ≥12months follow up after treatment started & date of first normal ALT is known. 
Follow-up biopsy NIS available in 74 (of 86) and 195 (of 247) DGH and UH biopsies respectively. 
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Table 8.5: Centres with specialist nurses seeing patients (n=5) versus those without (n=23). 














a)   ≥90% of symptomatic patients 
start prednisolone~ within 4 months of 
diagnosis  
 
275/291 (95) ✓ 543/586 (93) ✓ 0.3 
b)  ≥90% Steroids continued ≥1 year* 
 
239/293 (83)  506/707 (77)  0.001 
c)  ≥80% had appropriate blood 
monitoring++ 
 
239/347 (69)  601/786 (76)  0.007 
d)  ≥90% attain normal serum ALT at 1 
year treatment*** 
 
250/298 (84)  589/693 (85)  0.66 
e)  ≥80% clinically decompensated 
patients¥ who did not improve on 
treatment were discussed with a 
transplant team 
 
45/48 (94) ✓ 96/102 (94) ✓ 0.93 
f)  ≥60% of those re-biopsied attain 
histological remission   
 
49/123 (40)  54/148 (36)  0.6 
g)  ≥75% do not develop de-novo 
cirrhosis 
 
276/302 (91) ✓ 596/648 (92) ✓ 0.76 
h)  New decompensation during 
follow-up (<21%) 
30/400 (8) ✓ 57/867 (7) ✓ 0.54 
~or equivalent (Budesonide/methylprednisolone/hydrocortisone) as proportion of symptomatic patients. 
*In those followed up ≥1 year.  
++Liver Blood tests documented at 3 months, 6 months & 12 months adjusted for length of follow-up. 

















a)   ≥90% of symptomatic  patients 
start prednisolone~ within 4 months of 
diagnosis  
 
675/722 (93) ✓ 143/155 (92) ✓ 0.58 
b)  ≥90% Steroids continued ≥1 year* 
 
712/820 (75)  133/180 (74)  0.83 
c)  ≥80% had appropriate blood 
monitoring++ 
 
694/920 (75)  146/213 (69)  0.04 
d)  ≥90% attain normal serum ALT at 1 
year treatment*** 
 
684/794 (86)  155/179 (87)  0.87 
e)  ≥80% clinically decompensated 
patients¥ who did not improve on 
treatment were discussed with a 
transplant team 
 
122/130 (94) ✓ 19/20 (95) ✓ 0.84 
f)  ≥60% of those re-biopsied attain 
histological remission   
 
78/230 (34)  25/53 (47)  0.07 
g)  ≥75% do not develop de-novo 
cirrhosis 
 
694/761 (91) ✓ 178/189 (94) ✓ 0.18 
h)  New decompensation during 
follow-up (<21%) 
66/1033 ✓ 21/234 (9) ✓ 0.27 
~or equivalent (Budesonide/methylprednisolone/hydrocortisone) as proportion of symptomatic patients. 
*In those followed up ≥1 year.  
++Liver Blood tests documented at 3 months, 6 months & 12 months adjusted for length of follow-up. 
***In those with ≥12months follow up after treatment started & date of first normal ALT is known. 
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a) ≥90% of symptomatic patients 
start prednisolone~ within 4 months 
of diagnosis  
 
228/238 (96) ✓ 590/639 (92) ✓ 0.07 
b) ≥90% Steroids continued ≥1 year* 
 
218/281 (78)  527/719 (73)  0.16 
c) ≥80% had appropriate blood 
monitoring++ 
 
272/316 (86) ✓ 568/817 (69)  <0.001 
d) ≥90% attain normal serum ALT at 
1 year treatment*** 
 
253/275 (92) ✓ 586/698 (84)  0.001 
e) ≥80% clinically decompensated 
patients¥ who did not improve on 
treatment were discussed with a 
transplant team  
 
34/37 (92) ✓ 107/113 (95) ✓ 0.53 
f) ≥60% of those re-biopsied attain 
histological remission^   
 
52/130 (40)  51/151 (33)  0.28 
g) ≥75% do not develop de-novo 
cirrhosis 
 
252/274 (92) ✓ 620/676 (92) ✓ 0.89 
h) New decompensation during 
follow-up (<21%) 
19/356 (5) ✓ 68/911 (7.5) ✓ 0.17 
~or equivalent (Budesonide/methylprednisolone/hydrocortisone) as proportion of symptomatic patients. 
*In those followed up ≥1 year.  
++Liver Blood tests documented at 3 months, 6 months & 12 months adjusted for length of follow-up. 
***In those with ≥12months follow up after treatment started & date of first normal ALT is known. 
 
8.5 Discussion 
This is the first multicentre audit of both resources and of adherence to pre-defined standards 
regarding management of AIH.  
 
Only limited development of sub-specialisation amongst Gastroenterology and Hepatology 
physicians and nurses in regard to management of AIH was found. Nearly one-third of centres did 
not employ a Hepatologist. In half of centres (all DGH’s), at least half of the Consultants managed 
AIH, a median of 92% did so. One-third of centres have no Specialist liver nurse and less than 20% 
have a nurse reviewing patients with AIH. Finally, most hospitals do not have departmental 
guidelines for AIH. This situation contrasts with that for chronic viral hepatitis.  Indeed, the lack of 
Nurses may result from the lack of funding of Specialist Liver Nurses, which for Hepatitis C has 
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sometimes been sourced from Pharmaceutical Companies aiming to facilitate drug treatment. 
Business cases to develop such posts are challenging for rarer diseases such as AIH alone. 
 
Approximately 40% of hospitals did not have a Histopathologist with a specialist interest in liver 
disease and that these centres were less likely to report rosettes on the liver biopsy report. This 
underlines our earlier impression210 that histopathological AIH findings may have been under-
reported, which may lead to diagnostic uncertainty.  
 
The majority of hospitals do not have departmental guidelines for AIH, such guidelines might be of 
benefit, especially to those not coming across cases frequently. 
 
Of the eight pre-defined management standards, five (Table 8.2, standards a,e,g,h were met in the 
overall patient population; however two of these (a and e) were met only in only 68% and 70% 
respectively of the individual centres.  For Standard (a): 8% of symptomatic patients whose 
commencement of treatment was delayed by >4 months, it is likely that patient’s quality of life was 
reduced for this period. In most cases the reason for the delay wasn’t clear. Standard (e) is based on 
UK guidelines which state that clinically decompensated patients should be discussed with a 
transplant teams unless there is a clear contraindication, as this is associated with poor outcome. 
1,23,26  Although the pre-defined standard of 80% was met, it is still of concern that 7 of 150 with 
decompensation, which did not apparently improve with treatment, were not discussed with a 
transplant centre, despite being apparently eligible (based on age and absence of stated 
comorbidity). 
 
The other four pre-defined standards (Table 8.2: b-d and f) were not met in the overall patient 
cohort and in 14-26 of the 28 centres. In one-quarter of cases, steroids were discontinued after less 
than 12 months; reasons provided included side effects, compliance and uncertain diagnosis but in 
over 70% of patients, the reason was unclear.  The case for continuing steroid therapy for more than 
1 year is based on fact that histological remission lags behind biochemical remission by about six 
months and is achieved by only half of patients after a year.1 Histological activity may persist even in 
patients who achieve biochemical normalisation and is associated with failure of fibrosis regression 
and reduced long-term survival. 117  However, it remains unproven that longer duration of 
corticosteroid therapy is associated with improved longer-term outcome.23,207 Therefore it is 
debatable that this should be accounted for when considering treatment withdrawal.  
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Patients on Thiopurines and other immunosuppressive drugs need to have blood tests monitored at 
least every three months.1 This is because of their often narrow therapeutic index and the potential 
of haematological, renal and hepatic impairment, especially in those with pre-existing dysfunction, 
and in elderly patients. Our results suggest that 50% of centres fall short of this with a wide variation 
in monitoring practice shown by the range of percentages (3-100%) with adequate liver test 
monitoring. We did not ascertain whether patients not having liver tests checked had renal function 
and full blood count monitoring was not examined, but this seems unlikely. 
 
Recently published data suggest that remission rates were poorer in non-transplant centres (55% 
versus 62%). 211 However, when we compared DGH’s to UH’s we did not find significantly reduced 
rates of biochemical remission at 1 year (both 86%, p=0.73). 
 
A greater percentage of patient cases met minimum standards in centres we believe to have full 
capture compared to those who did not search all modalities (coding, histology, electronic databases 
and clinical letters). However, the presence of complete case capture did not have any overall 
impact on attainment of standards apart from blood monitoring, arguing against any case selection 
bias by centres.  
8.6 Conclusions 
This study shows that there is wide variability in service provision for AIH across hospitals in the UK, 
with better staffing of specialist Physicians, Histopathologists and nurses at University Hospitals than 
DGH’s.  In many hospitals, AIH is managed by a larger number of Physicians than seems necessary 
and there is a case for having patients with AIH under the care of a limited number of designated 
Physicians (either Gastroenterologists or Hepatologists). 
 
Furthermore, several of our pre-defined management standards were not met; either in the overall 
cohort of patients or in most of the individual centres. Whilst the importance of some of the 
standards in regard to patient outcome could be debated (for example, duration of steroid therapy), 
the >4 month delay in starting treatment (albeit only in 7% of patients, widespread failure to meet 
blood monitoring standards and the failure to discuss some apparently eligible patients with liver 
decompensation with transplant teams, are of some concern. This study was unable to show 
widespread differences between different types of hospital regarding meeting standards. Finally, we 
show that Histopathologists with a specialist interest in liver disease improve reporting at least some 
histological findings associated with AIH.   
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These findings support the case for improved liaison between services, such as monthly 
histopathology review (ideally via hospital link/teleconference); which would encourage discussion 
of clinical cases, pool experience, provide training and encourage adherence to guidelines. All of 
which are likely to improve patient care. 
 
Finally, it is hoped that participation in this audit will encourage improvements in care for patients 
with AIH, who will likely benefit from being part of an audit database in their home centre, which 
will allow monitoring of their case (such a database pre-existed in only 10 of the 28 centres). The 
database should also assist in business case planning for more resource provision. 
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Appendix B: Initial Paper Clinical Proforma  
Please fill all fields; tick for yes and cross for no (or circle)  
Date of Diagnosis:                                     Ethnic Group:  
(Defined as: Date of diagnostic biopsy or if no biopsy then date of commencing steroids; if no biopsy 
and no treatment, discuss with coordinator) 
Also managed at another centre   enter which centre here………………… Please still enter all info below 
1. DEMOGRAPHICS and CO-MORBIDITY (give year of diagnosis if known)  
Age at diagnosis: 
 
Height: 
 Weight at diagnosis:  Smoker:      Yes    Ex-  or  Never 
 
 Y N Year  Y N Year 
Diabetes    PBC or PSC (specify):    
Chronic lung disease    Cancer (specify):    
Cerebrovascular disease    Heart disease: 
• Ischaemic 
• Other (specify): 
   
 
2. PRESENTING FEATURES: 
Jaundice/itching  Rash  Asymptomatic  
Weight Loss  Fatigue  Other: 
Nausea  Amenorrhoea  Date 1st abnormal LFTs: 
Joint aches  ‘Flu’ like symptoms  
 
3. SEVERITY INDICES (at presentation) 
 Y N  Y N 
Cirrhosis/Portal hypertension: 
• Varices on imaging 
• Varices on endoscopy 
• Fibroscan Score 




• Variceal bleed 
• Hepatocellular carcinoma 
   
Other evidence (specify): 
 
4. FOLLOW-UP BIOPSY  
Follow up Biopsy done? Y/N   
Follow-up biopsy 1 done (date)                             Follow-up biopsy 2 done (date)                            
Iskak necroinflammatory score: 
OR               Minimal 
                    Mild 
                    Mod/severe 
 Ishak necroinflammatory score: 
 OR              Minimal 
                    Mild 
                    Mod/severe 
 
  
Ishak fibrosis score: Ishak fibrosis score: 
 
 
5. PREGNANCY (since diagnosis of AIH) 
Number of pregnancies 
 
 
 Relapse during pregnancy Y  N   Date: 
144 
Number of births  Relapse after pregnancy Y  N   Date: 
And Dates if known: 
 
6. SUBSEQUENT FIRST DEVELOPMENT OF COMPLICATIONS (please circle which and state mo and 
yr) 
 Y Mo/Yr  Y Mo/Yr 
New cirrhosis:    
 
• Follow-up  liver biopsy         
(not cirrhotic on prev. biopsy)           
• Varices (imaging/endoscopy)  
• Fibroscan score 
 
  Decompensation: 
• Variceal bleed  
• Ascites/oedema 
• Encephalopathy 
• MELD score >15 















Hepatoma   
Other evidence of cirrhosis (specify): 
 
Portal vein thrombosis             
Hepatopulmonary syndrome       
 
  
Other Cancers (specify sites): 
 
7. SUBSEQUENT HOSPITAL EPISODES RELATED TO LIVER DISEASE (excluding day case admissions 
for liver biopsy) 
Number Dates Reasons: 
   
   
 
8. DEVELOPMENT OF OTHER LIVER DISEASE (please circle and date) 
PBC Basis: AMA +ve or Biopsy NAFLD Basis:  Imaging/Biopsy 
PSC                      Basis: Imaging/Biopsy Other                  Basis:  
 
9. LATEST RECORDED STATUS  
Died: Y/N                 date: If Cancer specify type here: 
 Cause of death: 
• Liver failure 
• Variceal bleed 
• Hepatoma 
• Extra Hepatic cancer 



















10. REFERRAL FOR TRANSPLANTATION? (Please tick appropriate box) 




Referred       Y   N                date:  Assessment pending  
Reason why not referred (tick all that apply):  
• Not needed 
• Co-morbidity                         





Accepted, awaiting  
Not accepted 
Reason not accepted: 
• Not needed 
• Co-morbidity 







FLOW CHART FOR LIVER TESTS 
 
Date treatment started:___________ 
 
BASELINE BLOOD TESTS 
 Date ALT AST Bili Alb Creat Glob IgG PT 
/INR 
First available          
Peak values 
(ALT/AST) 
         
Values at start 
of treatment  
    
First Normal  
(ALT and/or AST) 
    
 
ONGOING MONITORING  
(Give first available value within time period) 
 Date  ALT AST Bili Alb Glob IgG 
Day 7*        
D. 28*        
Month 3        
Month 6        
1 year        
*or nearest day 
 
For each parameter, tick box if all normal during year; cross if at least one abnormal value: 
 Start Date  ALT   AST Glob IgG 
2nd year      
3rd year      
4th year      
5th year      
6th year      
7th year      
8th year      
RELAPSES 
Document all relapses, defined as ALT or AST rising to > twice upper normal limit from prior 
normal values. Date of relapse =date first abnormal AST or ALT 
Relapse 
Number 





Peak AST Bili IgG Date of first 
normal 
ALT/AST 
1        
2        
3        
4        







FLOW CHART FOR DRUG THERAPY 
• State drug and total daily dose in mg: thus, prednisolone 40mg od = pred 40;  Budesonide 
9mg od = Bud 9; Azathioprine 125mg od =  Aza 125 
• Other drugs: Mycophenolate (MMF), Cyclosporine (CYC), Tacrolimus (Tac) 















     
      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
DRUG TOXICITY (tick if occurred and state month after starting when SE occurred) 
STEROIDS                                AZATHIOPRINE/6MP/MMF      
 Y month  Y month 
Psychosis    White cell count <2.5 (and fall of 
>1.0)  
  
Diabetes (onset during treatment)   Pancreatitis   
Low trauma fracture   Other (specify): 
Other (specify): 
 
Free text; please add any clinically relevant information which has not previously been included:  
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